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Summary 
 
Tumor progression is usually associated with abnormal myelopoiesis and recruitment of 
several myeloid cell subsets into tissues. These cells heavily infiltrate the primary tumor 
and sustain its growth by providing local immune suppression and promoting 
angiogenesis. They also assist metastatic spreading by favoring the tumor invasion of 
adjacent tissues, and by supporting cancer cell seeding into distant sites. Recent advances 
have partially highlighted the mechanisms through which myeloid cells are recruited into 
the tumor mass and suppress the immune response against tumor cells, thus laying the 
basis for new antitumor immunotherapeutic approaches. However, very little is known 
about the molecular pathways which regulate myeloid cell differentiation and functions 
within the tumor microenvironment, especially in the context of the metastatic process. 
To obtain starting cues about new relevant molecular pathways acting in tumor-
infiltrating myeloid cells, we performed gene expression analysis in purified CD11b+ 
intratumoral myeloid cells isolated from different transplantable murine tumor models. 
Among the most upregulated genes, we got particularly interested in the disabled 
homolog 2, mitogen-responsive phosphoprotein (Dab2) gene. The DAB2 protein is a 
molecular adaptor which participates to endocytosis and signal transduction pathways. Its 
main function is to link membrane receptors with clathrin assemblies, allowing selective 
clathrin-mediated endocytosis of transmembrane proteins. The vesicular trafficking has 
the important function to distribute and organize the protein content of the plasma 
membrane, allowing the cell to spatially react to external stimuli. We thought that this 
process is of key-importance within the tumor microenvironment, where complex cell-to-
cell interactions occur and oriented stimuli are released. 
In this work we show that, once within the tumor, both monocytes and macrophages 
upregulated the DAB2 protein. Both the cytokines GM-CSF and M-CSF, which regulate the 
development of mononuclear phagocytes, were able to induce DAB2 expression by 
myeloid cells in vitro, through a mechanism requiring the transcription factor C/EBPβ. 
Conditional knockout of the Dab2 gene in the hematopoietic system resulted in a strong 
reduction of tumor-infiltrating monocytes and macrophages. In vivo tracking experiments 
showed that Dab2-knockout (Dab2-/-) monocytes were less efficient to generate tumor-
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associated macrophages than wild type ones, and this was accompanied by reduced 
recovery of Dab2-/- monocytes within the tumor mass. In vitro differentiation of bone 
marrow-derived macrophages indicated that Dab2-/- monocytes cannot efficiently carry 
out the autophagy process, suggesting a molecular mechanism that could explain their 
macrophage differentiation defects. Moreover, Dab2-/- tumor-associated macrrophages 
had increased expression of genes and membrane markers associated with the M2 
macrophage polarization. Finally, we found that spontaneous generation of metastases 
was impaired in Dab2-/- mice. These data strongly indicate that DAB2 is required for 
correct differentiation of tumor-associated macrophages, and suggest that this protein 
may be an optimal molecular target to obstruct myeloid cell-assisted dissemination of 
metastases in tumor-bearing hosts. 
3 
 
Riassunto 
 
La progressione della malattia neoplastica è solitamente accompagnata da una 
mielopoiesi anormale, con il richiamo di diverse sottopopolazioni mieloidi nei tessuti. 
Queste sottopopolazioni infiltrano fortemente il tumore primario e sostengono la sua 
crescita fornendo immunosoppressione e stimoli pro-angiogenici. Queste cellule 
assistono anche il processo metastatico favorendo l’invasione tumorale dei tessuti 
adiacenti, e sostenendo l’attecchimento delle cellule tumorali nei siti metastatici. Recenti 
scoperte hanno parzialmente compreso i meccanismi attraverso i quali le cellule mieloidi 
sono richiamate nella massa tumorale per sopprimere la risposta immunitaria contro le 
cellule tumorali, ponendo così le basi per nuovi approcci immunoterapeutici. Tuttavia, i 
meccanismi molecolari che regolano il differenziamento e le funzioni delle cellule mieloidi 
nel microambiente tumorale sono poco conosciuti, specialmente nel contesto del 
processo metastatico. 
Per ottenere indizi iniziali riguardo nuove vie molecolari che agiscono nelle cellule 
mieloidi infiltranti il tumore, abbiamo effettuato un’analisi dell’espressione genica in 
cellule mieloidi CD11b+ intratumorali purificate da diversi modelli murini di tumore 
trapiantabile. Fra i geni più espressi, abbiamo trovato particolarmente interessante il 
gene disabled homolog 2, mitogen-responsive phosphoprotein (Dab2). La proteina DAB2 
è un adattatore molecolare che partecipa all’endocitosi e a diverse vie di trasduzione del 
segnale. La sua principale funzione è di collegare i recettori di membrana con i 
raggruppamenti di clatrina, permettendo l’endocitosi selettiva delle proteine di 
membrana mediata dalla clatrina. Il traffico vescicolare ha l’importante funzione di 
distribuire ed organizzare il contenuto proteico della membrana plasmatica, consentendo 
alla cellula di reagire spazialmente agli stimoli esterni. Riteniamo che questo processo sia 
di importanza chiave all’interno del microambiente tumorale, dove avvengono complesse 
interazioni fra cellule e sono rilasciati stimoli orientati. 
In questo lavoro mostriamo che, raggiunto il tumore, sia i monociti che i macrofagi 
esprimono la proteina DAB2. Le citochine GM-CSF ed M-CSF, le quali regolano lo sviluppo 
dei fagociti mononucleati, inducono l’espressione di DAB2 nelle cellule mieloidi in vitro, 
attraverso un meccanismo che richiede il fattore di trascrizione C/EBPβ. Il knockout 
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condizionale del gene Dab2 nel sistema ematopoietico porta ad una forte riduzione dei 
monociti e macrofagi infiltranti il tumore. Esperimenti di tracciamento in vivo dei 
monociti Dab2-knockout (Dab2-/-) mostrano che questi ultimi, rispetto ai monociti wild 
type, sono meno efficienti nel generare i macrofagi associati al tumore, e questo effetto si 
accompagna con un ridotto recupero dei monociti Dab2-/- all’interno della massa 
tumorale. Il differenziamento in vitro di macrofagi ottenuti dal midollo osseo indica che i 
monociti Dab2-/- non riescono a sostenere efficientemente il processo autofagico, 
suggerendo un meccanismo molecolare che può spiegare il loro difetto di 
differenziamento in macrofagi. Inoltre, i macrofagi Dab2-/- associati al tumore hanno 
un’aumentata espressione di geni e marcatori di membrana correlati con la 
polarizzazione macrofagica M2. Infine, abbiamo scoperto che i topi Dab2-/- sono resistenti 
alla formazione di metastasi. Questi dati indicano fortemente che DAB2 è necessario per 
il corretto differenziamento dei macrofagi intratumorali, e suggeriscono che questa 
proteina potrebbe essere un ottimo target molecolare per ostacolare la disseminazione di 
metastasi assistita dalle cellule mieloidi negli individui con tumore. 
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Introduction 
 
Cancer is a pathologic multistep process in which normal cells acquire the ability to 
proliferate without control and spread throughout the body, usually killing their host in 
this process. To become malignant, neoplastic cells need to acquire several traits, which 
are common to all types of cancer and have been defined as “the eight hallmarks of 
cancer” (Hanahan and Weinberg 2011): 
1. Sustaining proliferative signaling; 
2. Evading growth suppressors; 
3. Resisting cell death; 
4. Enabling replicative immortality; 
5. Inducing angiogenesis; 
6. Activating invasion and metastasis; 
7. Deregulating cellular energetics; 
8. Avoiding immune destruction. 
Hallmarks 1-4 render neoplastic cells “masters of their own destiny”, allowing them to 
sustain chronic proliferation. This requires the subversion of the homeostatic control, 
which ensures normal tissue architecture and function. Hallmark 5 secures cell 
requirement for oxygen and nutrients, and give malignant cells an opportunity to enter 
the bloodstream and colonize distant tissues, which translates into hallmark 6. In order to 
sustain cell anabolism, hallmark 7 limits energy production largely to aerobic glycolysis 
(Lunt and Vander Heiden 2011). This ensures the availability of various glycolytic 
intermediates, which fuel both nucleoside and amino acid biosynthetic pathways. Finally, 
hallmark 8 allows cancer cells to avoid immune detection and escape immune 
surveillance (Schreiber, Old et al. 2011). 
The earliest vision of tumor progression postulated that all these traits are acquired by 
tumor cells only through genetic/epigenetic mutations and genomic instability, thinking 
that tumor biology could be understand simply elucidating the cell-intrinsic properties of 
cancer cells. However, research in the past decade has recognized tumors as complex 
organs in which recruited normal cells, composing the tumor-associated stroma, are 
essential to achieve most if not all the eight hallmarks of cancer (Hanahan and Weinberg 
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2011). With this concept in mind, we can assume that transformed tumor cells are not 
self-sufficient in their needs and so they recruit normal cells to receive assistance. For this 
reason, research efforts aiming to oppose cancer disease have focused on understanding 
the single cell types that compose the tumor microenvironment and how they 
orchestrate to manage tumor progression. 
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Components of the tumor microenvironment 
 
Cancer cells and cancer stem cells 
Cancer cells are the drivers of the disease, carrying the oncogenic and tumor suppressor 
mutations that confer them malignancy. Traditionally, cancer cells were believed to have 
a relative stable homogeneity within the tumor mass, until continuous proliferation 
(combined with genomic instability) spawn distinct clonal subpopulations. This clonal 
heterogeneity makes the tumor mass a mosaic of different regions with various degrees 
of differentiation, proliferation, and invasiveness. Recently, a new dimension of 
heterogeneity has been added by the discovery of the cancer stem cells (CSCs). CSCs are a 
rare subpopulation of cancer cells defined by the ability to efficiently seed new tumors 
when injected in recipient host mice (Cho and Clarke 2008). CSCs also express markers 
shared with normal stem cells of their tissue of origin (Al-Hajj, Wicha et al. 2003). CSCs 
may account in major part for the regenerative ability of tumors, providing to their own 
self-renewal and, at the same time, generating more differentiated progenies, which 
constitute the great bulk of the tumor mass. It is believed that CSCs arise from genetic 
mutations that disrupt the proliferative and differentiation program of normal stem cells 
(Lobo, Shimono et al. 2007). The presence of CSCs has important implications in therapy, 
because these cells are more resistant to many commonly used chemotherapeutic 
treatments (Creighton, Li et al. 2009; Singh and Settleman 2010). This trait, combined 
with their cancer stemness ability, could explain the almost certain relapse which, sooner 
or later, occurs after successful chemotherapy. Moreover, several studies have 
highlighted that activation of the epithelial to mesenchymal transition (EMT) program by 
cancer cells, which is fundamental for invasion and metastatic spreading (Katsuno, 
Lamouille et al. 2013), confers many features of CSCs (Mani, Guo et al. 2008; Singh and 
Settleman 2010). This finding suggests that the same transcriptional program that allows 
cancer cells to disseminate into distant sites, also allows them to locally proliferate and 
establish new tumors. 
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Endothelial cells 
Endothelial cells form the tumor-associated vasculature. Cancer cells need constant 
supply of oxygen and nutrients, and to fulfill this demand they induce the “angiogenic 
switch”, a cellular program that activates quiescent endothelial cells in order to construct 
new vessel (Hanahan and Folkman 1996). This process is regulated by a network of 
several signaling pathways, including the vascular endothelial growth factor (VEGF), 
angiopoietin, fibroblast growth factor (FGF), Notch, Neuropilin, Robo, and Eph-A/B signals 
(Carmeliet and Jain 2000; Ahmed and Bicknell 2009; Dejana, Orsenigo et al. 2009; 
Pasquale 2010). Recent researches  have unveiled gene expression profiles of tumor 
endothelial cells, thus allowing to identify distinct luminal surface markers that are not 
expressed on normal vessels. These studies have provided the opportunity to target 
specifically the tumor neo-vasculature with novel therapeutic strategies (Nagy, Chang et 
al. 2010; Ruoslahti, Bhatia et al. 2010). A particular kind of endothelial cells forms actively 
growing lymphatic vessels at the periphery of tumors and adjacent tissues. These vessels 
provide cancer cells with channels to seed metastases in draining lymph nodes (Tammela 
and Alitalo 2010). 
 
Pericytes 
Pericytes are mesenchymal cells with finger-like projections that wrap around the 
endothelial tubing of blood vessels. They provide paracrine signals to the quiescent 
endothelium, for example secreting low levels of VEGF with trophic function in 
endothelial homeostasis (Bergers and Song 2005). They also collaborate with endothelial 
cells in synthetizing the vascular basement membrane that sustains the hydrostatic 
pressure within blood vessels. Pharmacological inhibition of the platelet-derived growth 
factor (PDGF) receptor-mediated signaling in tumor pericytes reduced their coverage of 
tumor vessels, resulting in compromised vascular integrity and function (Gaengel, Genove 
et al. 2009). Intriguingly, pericytes of normal vessels were immune to such 
pharmacological destruction, providing another example of the therapeutic opportunities 
springing from the molecular diversity between normal and tumor vessels. 
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Cancer-associated fibroblasts 
Fibroblasts are often the major components of the tumor stroma. Within the tumor, two 
classes of fibroblasts can be found: (1) classic fibroblasts, which constitute the structural 
foundation supporting most epithelial tissues and (2) myofibroblasts, which are 
distinguished by expression of the α-smooth muscle actin (SMA) and can proliferate to 
physically sustain tissue repair (Hanahan and Weinberg 2011). Recruited myofibroblasts 
and reprogrammed variants of normal fibroblasts can enhance tumor proliferation, 
angiogenesis, invasion and metastasis. Fibroblasts can remodel the structure of the 
stroma through production of components of the extracellular  matrix (ECM), and are 
able to recruit endothelial cells and pericytes through secretion of growth factors and 
chemokines. Their pro-tumoral activities have been defined by transplantation of cancer 
cells admixed with cancer-associated fibroblasts in recipient mice, or by genetic and 
pharmacological perturbation of their functions (Kalluri and Zeisberg 2006; Shimoda, 
Mellody et al. 2010). 
 
Inflammatory leukocytes 
Understanding the regulation of immune cells within the tumor microenvironment and 
their influence on cancer progression is the main purpose of this study, so the following 
sections will focus on the current knowledge about these topics. 
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Properties and functions of tumor-infiltrating inflammatory 
leukocytes 
 
Histologic analysis of cancer biopsies indicate that virtually all tumors are infiltrated, 
although to various degrees, by leukocytes (Pages, Galon et al. 2010). These infiltrations 
are similar to those that arose in normal inflamed tissues, suggesting  that an 
inflammatory reaction usually occurs in tumors. Historically, this was interpreted as an 
attempt of the immune system to eradicate neoplastic lesions, which is partially true. 
However, in the last ten years it has become increasing evident that inflammation within 
the tumor microenvironment is created and controlled by cancer cells, through the 
recruitment of inflammatory cells mainly belonging to the myeloid branch of the immune 
system. From this point of view, inflammation is the occurrence of two opposite actions 
of immune cells: one tempting to control neoplastic growth and eliminate transformed 
cells, while the other favoring all the processes that cancer cells need in order to 
proliferate and seed elsewhere. 
 
The “good infiltrate”: theory of immune surveillance 
The theory of immune surveillance proposes that cells of the immune system constantly 
monitor tissues for the occurrence of malignant transformation, eliminating them before 
the onset of a clinically evident tumor can occur. The logical consequence is that tumor 
cells need to escape immune recognition and elimination in order to become a life-
threatening disease. This theory, initially proposed in the Fifties, received new attention 
thanks to the availability of transgenic mice that are deficient for various key components 
of the immune system (Schreiber, Old et al. 2011). Respect to immunocompetent 
littermates, these mice develop more frequently carcinogen-induced tumors, which grow 
more rapidly respect to controls. Moreover, cancer cells that arise in immunodeficient 
hosts fail to generate new tumors when transplanted in immunocompetent individuals, 
suggesting that tumor cells receive selective pressure from the immune system during 
their grow (Teng, Swann et al. 2008). The selective deficiency of particular immune cell 
types pinpointed a role for CD8+ cytotoxic T lymphocytes (CTLs), CD4+ TH1 helper T cells 
and natural killer (NK) cells in defending the host from tumor disease. Consistent with 
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these findings, colon and ovarian tumors, which are heavily infiltrated with CTLs and NK 
cells, have better prognosis than those lacking such infiltrates (Nelson 2008; Pages, Galon 
et al. 2010). Another clinical evidence comes from immunosuppressed organ transplant 
recipients who develop donor-derived cancers, suggesting that these cancer cells were 
kept in a dormant state by the functional immune system of the donor prior to 
transplantation (Strauss and Thomas 2010). 
To justify the occurrence of tumors in light of the immune surveillance theory, the three 
phase-model of “immunoediting” has been proposed (Schreiber, Old et al. 2011). The first 
phase is called “elimination”: cancer cells are constantly eliminated by immune 
surveillance each time they arise. In the second phase of “equilibrium”, some cancer cells 
manage to survive to immune elimination, and  a balance is established in which tumor 
cells constantly adapt and survive to the attempts of eradication by the immune system. 
In this phase immune killer cells (mainly CD8+ CTLs and NK cells) are still able to eliminate 
tumor clones that are excessively immunogenic or to deliver cytostatic signals that keep 
cancer cells dormant. It is believed that the equilibrium phase can persist even for 
decades, before cancer cells become fully competent in evading the immune system of 
the host. In the third phase, called “escape”, immune cells cannot eliminate tumor cells. 
Predictably, during the equilibrium phase there is a selective pressure for those tumor 
clones that somehow become less immunogenic (for example down-regulating the 
antigen presentation machinery); however it is increasingly evident that part of tumor-
infiltrating leukocytes, together with the environmental conditions established within the 
tumor microenvironment, actively suppress the cell-mediated immune response against 
cancer cells. 
 
The “bad infiltrate” and the “ugly outcome”: smoldering inflammation subverts anti-
tumor immunity and promotes cancer disease 
Chronic inflammation predisposes individuals to various types of cancer (Balkwill and 
Mantovani 2001). For example, inflammatory bowel disease (IBD) is associated with 
increased risk of developing colorectal cancer (Waldner and Neurath 2009). Conversely, 
chronic administration of non-steroidal anti-inflammatory agents reduces the incidence 
of several tumor types (Chan, Ogino et al. 2007). The positive relationship between 
cancer and inflammation seems counterintuitive, because inflammation activates the 
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immune system and facilitates the elimination of tissue-perturbing elements. Actually, 
the tumor microenvironment shows signs of “smoldering” inflammation, which are 
insufficient to trigger a fully operational cell-mediated immune response (Balkwill, 
Charles et al. 2005). Nonetheless, this condition provides the tumor with growth factors 
and anti-apoptotic signals, sustains angiogenesis, activates EMT, and produces ECM-
remodeling enzymes, which facilitate invasion and extravasation into the bloodstream 
(Grivennikov, Greten et al. 2010). Importantly, it also establishes an immunosuppressive 
environment that actively suppresses the adaptive immune response against tumor cells. 
This is achieved by secreting anti-inflammatory cytokines that block the antitumor TH1-
type immune response (TGF-β, IL-10, IL-4, IL-13, M-CSF, VEGF, IL-6); by inhibiting correct 
maturation and activation of professional antigen presenting cells (APCs), which are 
essential for correct priming of T lymphocytes (Gabrilovich 2004); and by either disabling 
or eliminating T lymphocytes that have successfully activated their tumoricidal functions, 
this task mainly being performed by particular classes of immune suppressive cells 
(Gabrilovich 2004). Recruitment of these cells also leads to their migration into secondary 
lymphoid organs and induction of immune tolerance to tumor antigens, further impairing 
the anti-tumor immune response (Nagaraj, Gupta et al. 2007; Ugel, Peranzoni et al. 2012). 
Tumor-induced immune suppression has important therapeutic implications, because it 
represents the main obstacle when anti-cancer immunotherapies are attempted 
(Zitvogel, Apetoh et al. 2008). 
Chronic inflammation induced by infections or autoimmune diseases increases the risk of 
cancer and, once established, promotes its progression. However, inflammatory cells and 
mediators are present virtually in all tumors, also in those types for which there is no 
epidemiological basis for inflammation. An explanation for this is that oncogenes and 
tumor-suppressors, whose genetic modifications can induce neoplastic transformation, 
also coordinate inflammatory transcriptional programs. For example, in vitro constitutive 
activation of the protein tyrosine kinase RET in freshly isolated human thyrocytes, which 
is sufficient to induce papillary thyroid carcinoma in vivo, also induces several 
inflammation-related genes (Borrello, Alberti et al. 2005). These include colony-
stimulating growth factors (CSFs), which recruit and promote the survival of leukocytes; 
IL-1β, one of the main pro-inflammatory cytokines; cyclooxygenase 2 (COX2), which 
synthetize prostaglandins (another class of proinflammatory molecules); ECM-degrading 
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enzymes; and various chemokines that recruit myeloid cells and promote angiogenesis 
(CCL2, CCL20, CXCL8). These proteins were also found in thyroid tumor specimens taken 
by biopsy. Another example is offered by activated oncogenic components of the RAS-
RAF signaling pathway, which induces the production of tumor-promoting inflammatory 
chemokines and cytokines (Sparmann and Bar-Sagi 2004; Guerra, Schuhmacher et al. 
2007). 
Once inflammation is established, inflammatory cells are recruited in response to 
secreted chemokines, cytokines and prostaglandins (Mantovani, Allavena et al. 2008). 
These cells sustain inflammation itself and actively contribute to almost all tumor-
promoting processes, including angiogenesis, metastatic spreading and immune 
suppression. Tumor-infiltrating inflammatory leukocytes are mainly composed of myeloid 
cells and include dendritic cells, granulocytes, myeloid derived suppressor cells, Tie2-
expressing monocytes/macrophages and tumor-associated macrophages. 
 
Dendritic cells 
Dendritic cells (DCs) are terminally differentiated myeloid cells whose main property is to 
efficiently process and present antigens to T cells. They differentiate in tissues from bone 
marrow progenitors and, at least in part, from monocytes (Liu and Nussenzweig 2010). 
Two major subsets of DCs exist, with different morphology, phenotypes and functions (Liu 
and Nussenzweig 2010; Swiecki and Colonna 2010). Conventional DCs normally uptake 
antigens in peripheral tissues, but they do not functionally present them to T cells unless 
they are activated by “dangerous” stimuli. These stimuli include molecules associated 
with viruses, bacteria or damaged tissues and are commonly referred as pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs). Both PAMPs and DAMPs are recognized by evolutionary conserved receptors 
called toll-like receptors (Rotta, Edwards et al. 2003). Their effect is to induce maturation 
of immature DCs, which involves both expression of co-stimulatory molecules and 
cytokines to promote T cell activation, and upregulation of chemokine receptors that 
drive migration of DCs to lymph nodes. The other subsets are plasmacytoid DCs, which 
have a morphology reminiscent of plasma cells and secrete high amounts of Interferon-α 
in response to viral nucleic acids or self DNA (Swiecki and Colonna 2010). 
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DCs in tumor-bearing hosts do not adequately stimulate immune responses. Tumor-
secreted factors induce abnormal myelopoiesis that impair DC maturation, with three 
main results: decreased production of mature functionally competent DCs; accumulation 
of immature DCs at the tumor site; and increased production of immature myeloid cells 
(Gabrilovich 2004). Tumor-secreted factors that block DC maturation include macrophage 
colony-stimulating factor (M-CSF), IL-6 and VEGF, which mainly act through shifting DC 
precursors towards macrophage differentiation, and by activating the transcription factor 
signal transducer and activator of transcription 3 (STAT3). However, other factors within 
the tumor microenvironment alter DC differentiation. Hypoxia induces in DCs the 
transcription factor hypoxia-inducible factor 1α (HIF1α), which drives the expression of 
adenosine receptor A2B. Adenosine stimulation of DCs impairs their allostimulatory 
activity and causes them to drive the development of TH2 rather than TH1 helper T cells, 
thus mining the TH1-type antitumor immune response (Yang, Ma et al. 2010). Moreover, 
adenosine-treated DCs secrete VEGF, IL-6, IL-8, IL-10, COX2, transforming growth factor-β 
(TGFβ) and activate the enzyme indoleamine 2,3-dioxygenase (IDO), which all favor tumor 
progression in several ways (Novitskiy, Ryzhov et al. 2008). Lactic acid, which is abundant 
at the tumor site due to increased glycolytic catabolism, also induces dysfunction of DCs 
(Gottfried, Kunz-Schughart et al. 2006). Increased accumulation of lipids, which occurs in 
DCs isolated from tumor-bearing hosts, impairs DC ability to process soluble antigens and 
mount T cell responses (Herber, Cao et al. 2010). Not only tumor-infiltrating DCs (TIDCs) 
are dysfunctional, but also actively suppress CD8+ T cell responses, through expression of 
the immune suppressive molecules arginase 1 (ARG1), IDO, IL-10 and TGFβ (Norian, 
Rodriguez et al. 2009; Watkins, Zhu et al. 2011). Plasmacytoid DCs exert their immune 
suppressive activity mainly through expression of IDO (Munn, Sharma et al. 2004). This 
enzyme limits T cell growth by consuming local L-tryptophan; it also enhances the 
regulatory activity of Treg cells, a particular subset of CD4
+ T helper cells which maintains 
peripheral tolerance in tissues (Baban, Chandler et al. 2009). 
 
Granulocytes 
Granulocytes are leukocytes characterized by the presence of cytoplasmic granules and 
multi-lobed shape of the nuclei. The most abundant type of granulocytes in the body are 
the neutrophils, which can be distinguished from eosinophils and basophils on the basis 
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of their content by apposite histologic stainings. Neutrophils are phagocytic cells that 
rapidly respond to infections by destroying engulfed pathogens. They can be easily 
recognized in tissues by expression of the myeloid marker CD11b (also known as integrin 
αM) and LY6G, an isoform of the GR1 surface protein (Gabrilovich, Ostrand-Rosenberg et 
al. 2012). 
The role of tumor-infiltrating granulocytes in cancer is controversial. Neutrophils assist 
angiogenesis and metastasis in several metastatic tumor models. Tumors resistant to 
antiangiogenic therapy secrete granulocyte colony-stimulating factor (G-CSF), which 
induces production of neutrophils in the bone marrow and their recruitment to the 
tumor. Once there, neutrophils secrete prokineticin 2 (PROK2), which stimulates 
angiogenesis and compensates for the therapeutic effects of anti-VEGF therapy (Shojaei, 
Wu et al. 2007; Shojaei, Wu et al. 2009). Moreover, G-CSF induces early migration of 
Ly6G+Ly6C+ granulocytes in premetastatic lungs of tumor-bearing mice. Once in the 
premetastatic site, granulocytes secrete PROK2 that guides the arrival and seeding of 
metastatic cells through the activation of prokineticin receptor 1 (Kowanetz, Wu et al. 
2010). Granulocytes also facilitate angiogenesis through secretion of matrix 
metalloproteinase 9 (MMP9), which augments VEGF bioavailability through its release 
from the ECM (Nozawa, Chiu et al. 2006). In contrast with these reports, however, 
neutrophils were showed to inhibit the formation of metastasis in a model of 
transplantable murine mammary carcinoma. This was mediated through cytotoxic effect 
against tumor cells by production of reactive oxygen species (Granot, Henke et al. 2011). 
This dualistic role of neutrophils in cancer could be explained by the finding that these 
cells can acquire two opposite behaviors in the context of tumor disease (Fridlender, Sun 
et al. 2009). Tumor-infiltrating neutrophils become “N1” after TGFβ blockade, resulting in 
antitumor cytotoxic effects and secretion of proinflammatory cytokines. Conversely, 
depletion of “N2” neutrophils in untreated tumor-bearing control mice resulted in 
reduced tumor growth and increased activation of CD8+ CTLs. This “N2” state was 
characterized by expression of ARG1 and low levels of proinflammatory molecules. 
 
Myeloid-derived suppressor cells 
Tumor progression has two main consequences on myeloid cells. The first one is blockade 
of the differentiation program of several myeloid lineages, leading to the accumulation of 
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immature myeloid cells at the tumor site and secondary lymphoid organs.  The second 
one is induction of powerful immune suppressive activity against CD8+ CTLs (Gabrilovich, 
Ostrand-Rosenberg et al. 2012). Highly immune suppressive immature myeloid cells are 
defined as myeloid-derived suppressor cells (MDSCs), which have further been divided in 
polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs (M-MDSCs). Both these 
subsets have been described in cancer patients, although there are some differences in 
the hierarchy and the mechanisms of immune suppression between human and mouse 
species (Gabrilovich, Ostrand-Rosenberg et al. 2012). 
PMN-MDSCs exert their suppressive activity through production of reactive oxygen 
species (ROS), which down-regulate the T cell receptor (TCR) ζ-chain of CD8+ T cells 
(Schmielau and Finn 2001). PMN-MDSCs can be distinguished from granulocytes for their 
suppressive activity and for higher levels of CD115 and CD244 but lower levels of CXC-
chemokine receptor 1 (CXCR1) and CXCR2 than neutrophils (Youn, Nagaraj et al. 2008).  
M-MDSCs are mainly recognized for expression of CD11b and intermediate levels of GR1 
(Dolcetti, Peranzoni et al. 2010). They also express varying levels of classic monocyte 
markers as CD115, F4/80 and CC-chemokine receptor 2 (CCR2) (Youn, Nagaraj et al. 2008; 
Dolcetti, Peranzoni et al. 2010). Although this phenotype is reminiscent of inflammatory 
monocytes (discussed later), M-MDSCs are highly immune suppressive (even higher than 
PMN-MDSCs) and can co-express the enzymes inducible nitric oxide synthase (iNOS) and 
ARG1 (Gallina, Dolcetti et al. 2006). In contrast, inflammatory monocytes do not have a 
coordinate regulation of these two enzymes and are not immune suppressive. While iNOS 
expression alone confers tumoricidal activity to macrophages, concomitant expression of 
this enzyme with ARG1 results in production of peroxynitrite, which undermine CD8+ T 
cell responsiveness by desensitizing the TCR and interfering with IL-2 receptor signaling 
(Bronte and Zanovello 2005; Nagaraj, Gupta et al. 2007). By nitrating CC-chemokine ligand 
2 (CCL2), peroxynitrite also impair the ability of CD8+ CTLs to infiltrate the tumor mass, 
thus limiting their access to cancer cells for antigen-specific cell lysis (Molon, Ugel et al. 
2011).  
Synergistic role of ARG1 and iNOS in producing peroxynitirites is due to their sharing of 
the substrate L-arginine. Biochemical studies indicate that when iNOS catalyzes the 
synthesis of nitric oxide (NO) under sub-optimal concentration of L-arginine, the main 
product of the reaction becomes the anion superoxide O2
- (Xia, Roman et al. 1998). O2
- is 
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highly reactive and instantly combines with other molecules, thus generating reactive 
nitrogen-oxide species that include peroxynitrite. ARG1 alone is also immune suppressive: 
by depleting local L-arginine, ARG1+ MDSCs deprive lymphocytes of an essential nutrient, 
resulting in down-regulation of the TCR ζ-chain and blockade of antigen-stimulated 
proliferation (Bronte and Zanovello 2005). ARG1 also allows MDSCs to convert naïve CD4+ 
T helper cells into induced Treg cells (Serafini, Mgebroff et al. 2008), thus exerting another 
(indirect) inhibitory effect on CD8+ CTLs. Other mechanisms of Treg expansion by MDSCs 
include CD40-CD40L interactions and production of soluble factors as IFN, IL-10, TGFβ, 
and retinoic acid (Huang, Pan et al. 2006; Pan, Ma et al. 2010; Hoechst, Gamrekelashvili et 
al. 2011). 
MDSCs can migrate to secondary lymphoid organs (lymph nodes and spleen), where they 
exert their immune suppressive activity against CD8+ CTLs in an antigen-specific manner. 
CD11b+GR1+ cells were found in the lymph nodes of tumor-bearing mice and cancer 
patients, where they made CD8+ T lymphocytes unresponsive to antigen stimulation. 
Suppression required cell-to-cell contact between MDSCs and T cells and involved 
antigen-specific recognition between the TCR and peptide-major histocompatibility 
complex (MHC) class I dimers expressed by MDSCs (Nagaraj, Gupta et al. 2007). This 
allowed nitration of the TCR through short range-diffusion of peroxinitrite produced by 
MDSCs. TCR modification compromises its ability to recognize antigens exposed by MHC 
class I on APC cells, thus undermining T cell ability to mount antigen-specific responses 
(Nagaraj, Gupta et al. 2007). It is likely that the same mechanism also occurs in the 
spleen; however, we found that splenectomy is sufficient to restore completely CTL 
reactivity against tumor antigens (Ugel, Peranzoni et al. 2012). Further experiments 
indicated that CD11b+GR1int M-MDSCs have high proliferative potential and expand in the 
marginal zone of the spleen during tumor progression. In this site they closely associate 
with circulating CD8+ T lymphocytes, cross-presenting tumor antigens and inducing 
immune tolerance. Conversely, it is believed that tumor-infiltrating MDSCs inhibit nearby 
T cells without the need for cellular contact, resulting in antigen-unspecific suppression 
(Gallina, Dolcetti et al. 2006; Corzo, Condamine et al. 2010). Both ARG1 and iNOS are 
implicated in the process, probably through depletion of local L-arginine, production of 
NO, which interferes with IL-2 receptor signaling (Mazzoni, Bronte et al. 2002), and 
induction of Treg cells. Interestingly, IFN produced by activated CD8
+ CTLs and TH1 cells is 
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required to induce the immune suppressive activity of MDSCs, suggesting that these cells 
might represent a “shut down” system aimed to counteract excessive immune responses 
(Bronte, Wang et al. 1998; Gabrilovich, Ostrand-Rosenberg et al. 2012). 
Although MDSCs have been mainly characterized for their immune suppressive 
properties, several studies reported a role for immature myeloid cells in sustaining other 
fundamental processes of tumor progression (Gabrilovich, Ostrand-Rosenberg et al. 
2012). Examples are: support tumor invasion through secretion of MMP2 and MMP9 
(Kitamura, Kometani et al. 2007); angiogenesis promotion through secretion of MMP9 
and differentiation into endothelial-like cells (Yang, DeBusk et al. 2004); creation of a 
suitable environment for the arrival of cancer cells in future metastatic sites (Hiratsuka, 
Watanabe et al. 2006); induction of the EMT through TGFβ, epidermal grow factor (EGF) 
and hepatocyte grow factor (HGF) signaling pathways (Toh, Wang et al. 2011). 
Unfortunately, the majority of these studies did not verify whether these immature 
myeloid cells were immune suppressive or not, making improper to assert that they were 
indeed MDSCs. However, conditional deletion of the gene encoding p120 catenin, whose 
product is involved in cell-to-cell adhesion and signaling, caused the formation of invasive 
squamous cell cancer and desmoplasia in mice. Analysis of the tumor lesions showed 
production of several pro-inflammatory cytokines (GM-CSF, M-CSF, CCL2, TNFα) and 
accumulation of CD11b+GR1+CD124+ immune suppressive immature myeloid cells, which 
promoted tumor progression by converting normal fibroblasts in cancer-associated 
fibroblasts (Stairs, Bayne et al. 2011). It should be noted that immature myeloid cells are 
recruited early during tumor progression; acquisition of an immune suppressive program 
could occur later on, when consistent mounting of TH1-type adaptive immune response is 
sufficient to trigger MDSC functions (Gallina, Dolcetti et al. 2006; Marigo, Dolcetti et al. 
2008; Gabrilovich, Ostrand-Rosenberg et al. 2012), thus preventing cancer cells from 
being harmed. 
 
Tie2-expressing monocytes/macrophages 
A fraction of blood resident monocytes weakly express the angiopoietin (ANG) receptor 
Tie2, which modulates endothelial cell biology and destabilizes blood vessels to facilitate 
angiogenesis (Augustin, Koh et al. 2009). Once within the tumor, these monocytes 
upregulate Tie2 expression and differentiate in perivascular macrophages (De Palma, 
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Venneri et al. 2005; Pucci, Venneri et al. 2009). Their proximity to blood vessels suggests 
that these cells provide paracrine signals to the angiogenic vasculature. Consistently with 
this hypothesis, TEM-specific depletion in tumor-bearing mice reduced tumor vasculature 
and impaired tumor growth (De Palma, Venneri et al. 2003; De Palma, Venneri et al. 
2005).  TEMs isolated from mammary tumors display a distinctive gene expression 
signature consistent with increased proangiogenic activity and reduced proinflammatory 
activity respect to Tie2-negative tumor macrophages (Pucci, Venneri et al. 2009). ANG2 
stimulates leukocyte adhesion to vascular endothelium by enhancing expression of the 
adhesion protein intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion 
molecule 1 (VCAM1) on endothelial cells (Fiedler, Reiss et al. 2006). In vitro experiments 
demonstrated that ANG2-stimulated TEMs up-regulate the proangiogenic genes 
thymidine phosphorylase and cathepsin-B, and secrete several proangiogenic factors 
(Coffelt, Tal et al. 2010), indicating that ANG2 acts as a TIE2 agonist on TEMs to enhance 
their proangiogenic functions. 
24 
 
Tumor-associated macrophages: functional versatility on demand 
  
Macrophages are terminally differentiated myeloid cells that are specialized in engulfing 
pathogens and cellular debris through phagocytosis. Almost all tissues have a resident 
population of macrophages, whose markers and functions reflect their site of action. 
Their main functions in healthy individuals are to eliminate infectious agents, promote 
wound healing and regulate adaptive immunity. They also contribute to maintain tissue 
homeostasis by remodeling the ECM, clearing out apoptotic cells and monitoring immune 
activation. Macrophages are essential players during situations of intense tissue 
remodeling like embryogenesis, chronic inflammation, wound healing, fibrosis, and 
cancer (Mosser and Edwards 2008). 
Macrophages can acquire opposite roles in the context of immune responses. Usually the 
term “macrophage polarization” is used to indicate the acquisition of particular functional 
states. “M1” or “classically activated” macrophages are induced by IFN and microbial 
products, secrete high levels of IL-12 and low levels of IL-10, and can efficiently kill 
engulfed bacteria and intracellular pathogens. Unlike DCs, macrophages are not 
professional APCs, but M1 macrophages upregulate MHC class II and the co-stimulatory 
molecule CD86, which allow them to present antigens to CD4+ TH cells. This, combined 
with high secretion of IL-12, drives the induction of TH1 cells and the initiation of a TH1-
type adaptive immune response (Biswas and Mantovani 2010). M1 macrophages 
upregulate iNOS and ROS-generating enzymes, allowing the production of reactive 
nitrogen and oxygen intermediates. This allows efficient destruction of engulfed 
pathogens but can trigger tissue-disruptive reactions (Gordon and Taylor 2005).  
Conversely, “M2” or “alternatively activated” macrophages are induced by TH2 cell-
derived IL-4 and IL-13, which are produced during helminth infection and allergy. M2 
macrophages produce low levels of IL-12 and high levels of IL-10, thus precluding them 
from inducing TH1 cells. Conversely, they produce a distinct set of chemokines including 
CCL17, CCL22 and CCL24, which attract TH2 and Treg cells, thus amplifying TH2-type 
adaptive immune response and immune suppression (Biswas and Mantovani 2010). M2 
macrophages upregulate ARG1, allowing production of polyamines, which sustain 
vascularization and fibrosis for wound healing (Bronte and Zanovello 2005). ARG1 also 
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suppress CD8+ CTL responses through local depletion of L-arginine, as discussed above. It 
should be noted that, contrary to MDSCs, macrophages do not co-express both iNOS and 
ARG1, whose alternate expression reflects either the M1 or M2 polarization, respectively. 
Actually, macrophages are believed to form in vivo a continuum of phenotypes, with the 
full M1 and M2 polarizations being the extremities. The M1/M2 nomenclature is a useful 
oversimplification to understand the many functions that macrophages can potentially 
exploit within tissues. M1 and M2 macrophages were initially outlined based on their 
immune functions, but the M2 classification has been progressively expanded to include 
many other functional states, which are not strictly connected to immune responses. Few 
years ago, Mosser and Edwards proposed that M2 macrophages should be further divided 
in two partially overlapping groups, named “wound-healing macrophages” and 
“regulatory macrophages” (Mosser and Edwards 2008). Like the “classic” M2 group, 
wound-healing macrophages are induced by IL-4 and IL-13 and contribute to the 
clearance of parasitic infections. However, this new classification stress their ability to 
facilitate tissue repair. Through ARG1, these macrophages furnish polyamines and L-
proline, which are fundamental for the production of the ECM and nourishment of 
proliferating cells (Bronte and Zanovello 2005). From this point of view, the immune 
suppressive activity of ARG1 can be seen as another additional way to promote wound 
healing. Interestingly, the excessive fibrosis which is consequent to chronic 
schistosomiasis has been attributed to the uncontrolled activation of wound-healing 
macrophages (Hesse, Modolell et al. 2001). 
Regulatory macrophages are induced by anti-inflammatory stimuli like IL-10 and 
glucocorticoids (Mosser and Edwards 2008). In response to LPS, they produce high levels 
of IL-10 and low levels of IL-12, thus clearly contrasting with M1 proinflammatory 
macrophages. Interestingly, these regulatory macrophages can present antigens to T cells 
and also secrete TGFβ, suggesting that they can induce the development of antigen-
specific CD4+ Treg cells (Savage, de Boer et al. 2008). This macrophage subset has also 
been named “M2-like” macrophages (Biswas and Mantovani 2010). It must be pointed 
out that despite these differences, all those Authors agree that macrophages represent a 
circular continuum of phenotypes, with multiple overlapping functions, which can be 
individually attributed to discrete macrophage classification groups. 
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In the context of cancer, tumor-infiltrating M1 macrophages are cytotoxic to tumor cells 
and can sustain TH1-type antitumor immune response, while M2 and M2-like 
macrophages facilitate tumor progression (Gabrilovich, Ostrand-Rosenberg et al. 2012). 
Tumor-infiltrating macrophages with tumor-promoting functions are termed tumor-
associated macrophages (TAMs). Their presence among human tumor-infiltrating 
leukocytes is usually associated with poor clinical outcome (Qian and Pollard 2010). TAMs 
represent a mixture of M2-like macrophage subsets, which resemble those those 
promoting tissue formation during development (Pollard 2009). They essentially create an 
advantageous environment for cancer cells, supporting their growth and spreading. The 
multiplicity of functions exploited by macrophages in normal tissues reflects the number 
of tumor processes where TAMs can intervene. With regard to this, Jeffrey Pollard 
proposed five main classes in which TAMs can be divided (Qian and Pollard 2010). 
 
Immune regulation of the tumor microenvironment by tumor-associated macrophages 
TAMs are not efficient APCs and when tumor-infiltrating macrophages are purified and 
stimulated in vitro with microbial products, high levels of IL-10 and low/absent levels of 
IL-12 are measured in culture supernatants (Sica, Saccani et al. 2000). Consistently, TAMs 
do not support the activation of NK cells and TH1 cells and hence fuel the cell-mediated 
antitumor cytotoxic responses. Conversely, the high production of IL-10 induces the 
development of TH2 cells, whose secretion of IL-4 maintains the M2-like phenotype in 
TAMs (DeNardo, Barreto et al. 2009). CCL22 secretion by TAMs recruites Treg cells (Curiel, 
Coukos et al. 2004); it is also possible that IL-10 produced by TAMs enhances Treg cell 
activity, thus further strengthening immune suppression within the tumor (Murai, 
Turovskaya et al. 2009). In addition to their ability to skew CD4+ TH cells toward an 
immune regulatory phenotype, TAMs contribute directly to immune suppression of CD8+ 
CTLs by secreting TGFβ and prostaglandin E2 (PGE2), by up-regulating ARG1, and by 
expressing PD1 ligand 1 (PDL1) that binds to its receptor programmed cell death protein 1 
(PD1) on activated T cells (Murai, Turovskaya et al. 2009). Besides TH2 cells, also Treg cells 
promote macrophage M2 polarization by (1) inhibiting macrophage responsiveness to 
lipopolysaccharide (LPS), a prototype inducer of M1 polarization; (2) increasing expression 
of the mannose receptor CD206 and scavenger receptor CD163 in macrophages. This is 
achieved by secretion of IL-10, IL-4 and IL-13 (Tiemessen, Jagger et al. 2007). Tumor cells 
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also induce the M2 phenotype by secreting TNFα, which upregulates macrophage 
scavenger receptor types I and II (Summers, Rankin et al. 2010). 
Interesting, the composition of M1/M2 polarized intra-tumoral macrophages changes 
spatially and temporally during tumor progression. Through analysis of both Ly6C and 
MHC class II marker expression in tumor-infiltrating myeloid cells, Movahedi and 
colleagues were able to identify two distinct populations of TAMs (Movahedi, Laoui et al. 
2010). Molecular comparison of these two populations indicated that Ly6ClowMHC IIhi 
macrophages were more M1-oriented respect to Ly6ClowMHC IIlow macrophages, which 
had a prominent M2-like phenotype. During progression of either lung or mammary 
carcinoma, the percentage of Ly6ClowMHC IIlow macrophages progressively increased with 
respect to Ly6ClowMHC IIhi ones, indicating a progressive shift of tumor-infiltrating 
macrophages toward the M2 polarization. Interestingly, O’Sullivan and colleagues found 
that, in the absence of adaptive immunity, M1 macrophages become the main leukocyte 
population responsible for the immunoediting.  In this study M1 polarization was found to 
be induced by NK cell-secreted IFN at the tumor site (O'Sullivan, Saddawi-Konefka et al. 
2012). It could be speculated that tumor-infiltrating macrophages, continuously recruited 
by tumor inflammatory stimuli, can acquire an M1-oriented phenotype in the presence of 
IFN secreted by NK cells and/or IFN-secreting T lymphocytes. However, during tumor 
progression, there is a shift toward a progressive accumulation of M2-oriented 
macrophages, possibly due to deletion of IFN-producing cells and interaction of 
macrophages with the regulatory elements of the adaptive immune system. Polarization 
of macrophages is controlled at the transcriptional level by nuclear factor κB (NF-κB), 
which is the central transducer of signals that cause inflammation downstream of TLR 
activation (Karin and Greten 2005). NF-κB activity induces the expression of IL-12, TNFα 
and iNOS, which are hallmarks of M1 polarization. NF-κB signaling in tumor-infiltrating 
macrophages is inhibited by massive overexpression of the p50 NF-κB inhibitory subunit. 
p50 homodimers translocate to the nucleus and negatively regulate NF-κB activity; as a 
consequence, macrophages display the M2-like phenotype (Saccani, Schioppa et al. 
2006). 
Another class of transcription factors that regulates macrophage polarization is the signal 
transducer and activator of transcription (STAT) family, in particular the STAT1, STAT3 and 
STAT6 members. STAT1 is activated in response to M1-orienting signals; however its role 
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in the context of immune surveillance is controversial. Experiments with mice lacking 
functional STAT1 have shown increased resistance to chemical induction of tumors 
(Kaplan, Shankaran et al. 1998), and these results were confirmed using preclinical tumor 
models (Zhou, Wang et al. 2001; Lesinski, Anghelina et al. 2003). However, other studies 
have shown a protumoral role for STAT1. For example, STAT1-activation in TAMs was 
necessary for suppression of T cell responses in transplantable models of fibrosarcoma 
and colon-carcinoma (Kusmartsev and Gabrilovich 2005). Moreover, in a murine 
squamous cell carcinoma, STAT1 deficiency enhanced IL-12-mediated tumor rejection by 
a T cell-dependent mechanism (Torrero, Xia et al. 2006). These discrepancies could be 
attributed to the heterogeneity of examined tumor models. However, it should be noted 
that activation of IFN-dependent signaling, which requires STAT1,  is necessary for the 
induction of immune suppressive program in MDSCs (Gallina, Dolcetti et al. 2006). In this 
sense, abrogation of STAT1 activity could have a dualistic effect within the tumor-bearing 
host (abrogation of both M1 macrophage-mediated antitumor activity and MDSC-
mediated immune suppressive activity), and the net result on tumor growth could be 
dependent on the specific tumor model examined. 
STAT3 and STAT6 are associated with M2 macrophage polarization. STAT3 constitutive 
activation in TAMs leads to inhibition of proinflammatory cytokine production and release 
of factors which block DC maturation (Kortylewski, Kujawski et al. 2005). STAT3 has also a 
profound role in the cancer-associated block of immature myeloid cell maturation and DC 
development, as described later. TAMs from Stat6-/- mice display an M1 phenotype, with 
low levels of ARG1 and high iNOS-mediated production of NO, which promotes tumor cell 
death (Sinha, Clements et al. 2005). 
 
Proangiogenic TAMs 
TAMs greatly contribute to tumor angiogenesis. Depletion of these cells using the null 
mutation of the Csf1 gene, which encodes for the macrophage growth factor CSF-1, 
strongly impairs the angiogenic switch in mammary tumors, and this effect is reversed by 
re-expression of CSF-1 in the mammary epithelium (Lin, Li et al. 2006). Conversely, 
overexpression of CSF-1 in wild type mice results in premature accumulation of 
macrophages in hyperplastic lesions, with concomitant early appearance of the 
angiogenic switch and progression to malignancy (Lin and Pollard 2007). Similar results 
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were obtained in an osteosarcoma model and with different strategies of macrophage 
depletion (Zeisberger, Odermatt et al. 2006; Gazzaniga, Bravo et al. 2007; Kubota, Takubo 
et al. 2009). 
TEMs probably account for most of TAM contribution to angiogenesis. Transcriptional 
profiling of Ets2-deficient TAMs showed that the transcriptional factor ETS2 regulates the 
expression of many proangiogenic molecules, whose mRNA transcripts are enriched in 
TIE2+ TEMs with respect to TIE2- TAMs (Ojalvo, King et al. 2009; Zabuawala, Taffany et al. 
2010). Consistently, conditional ablation of the Ets2 gene in vivo inhibits angiogenesis 
(Zabuawala, Taffany et al. 2010). TEM transcriptional signature is predictive of poor 
survival when compared with available clinical databases (Ojalvo, King et al. 2009; 
Zabuawala, Taffany et al. 2010), which is in accord with the clinical observations in breast 
cancer correlating macrophage density with increased microvessel density and poor 
prognosis (Leek and Harris 2002). 
Macrophages constitutively express the transcription factor HIF1α (Murdoch, Muthana et 
al. 2008), which modulates their CCL2- and endothelin-mediated recruitment to tumor 
hypoxic areas. HIF1α also regulates the transcription of several genes associated with 
angiogenesis, including VEGF (Lewis and Hughes 2007). Macrophages not only can 
produce VEGF, but also make it available through the production of MMP9, which 
releases VEGF from extracellular depots (Giraudo, Inoue et al. 2004). CCL2 is generally 
required for recruitment of macrophages; however, in many tumor models CCL2 is 
dispensable because of the compensatory recruitment of MMP9-producing neutrophils 
(Pahler, Tazzyman et al. 2008). 
 
Macrophages assist cancer cells in all phases of the metastatic process 
Metastatic disease account for as much as 90% of cancer-associated mortality (Chaffer 
and Weinberg 2011). Although the majority of cancer clinical cases eventually end up 
with the occurrence of metastases, this process is very inefficient and requires multiple 
steps in order to be completed (Joyce and Pollard 2009). Supposing that a connection to 
blood vessels has been reached, metastatic  cells need to invade the surrounding stroma, 
intravasate into the blood stream, and extravasate in a distant site. Once there, 
metastatic cells must seed and proliferate in situ, which represents the most limiting step 
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(Joyce and Pollard 2009). Myeloid cells, in particular macrophages, play essential roles in 
all the process. 
A particular subset of invasive TAMs lead the way to cancer cells across the stroma. These 
macrophages are transcriptionally similar to fetal macrophages that promote tissue 
formation during embryogenesis (Ojalvo, Whittaker et al. 2010). They are enriched in 
developmental pathway genes, in particular the Wnt signaling pathway. It has been 
shown in vitro that co-culture of tumor cells with macrophages induces the expression of 
Wnt5a in the latter. This regulates tumor cell migration through activation of the Wnt 
non-canonical pathway, while in macrophages it determines expression of MMP7 that 
increases their ECM-remodeling ability (Pukrop, Klemm et al. 2006). 
Macrophage assistance to breast tumor invasion requires a strict interplay with cancer 
cells. These cells, in fact, synthetize M-CSF that stimulates macrophages to move and 
produce EGF, a factor that in turn activates migration of the tumor cells (Wyckoff, Wang 
et al. 2004). Both cell types require each other continuous assistance to progress into 
tissues by this mechanism, and inhibition of either M-CSF or EGF signaling completely 
blocks the entire process. Several in vitro experiments have demonstrated that 
macrophages and tumor cells are sufficient for this paracrine interaction (DeNardo, 
Barreto et al. 2009; Green, Liu et al. 2009). M-CSF production by mammary tumor cells is 
regulated by steroid hormone receptor coactivator-1 (SRC-1), and SRC-1 deficiency in vivo 
impairs macrophage recruitment and inhibits tumor intravasation without affecting 
tumor growth (Wang, Yuan et al. 2009). IL-4 produced by either CD4+ TH2 cells or tumor 
cells is also required to induce the invasive phenotype in macrophages (DeNardo, Barreto 
et al. 2009). Several cytokines, like heregulin and CXCL12, can initiate the co-migration of 
tumor cells and macrophages, but the M-CSF/EGF paracrine loop is always required to 
sustain it (Hernandez, Smirnova et al. 2009). Importantly, M-CSF is abundant at the 
invasive edge of human tumors, a site abundantly populated by macrophages (Lin, Leu et 
al. 2011). 
The ECM plays a major role in cancer invasiveness. Macrophages secrete osteonectin, 
which is important for deposition of collagen IV. Interestingly, osteonectin is necessary for 
spontaneous metastases from the primary tumor (Sangaletti, Di Carlo et al. 2008). 
Macrophages and tumor cells move approximately ten times faster on collagen structures 
than through the stroma itself. These collagenous fibrils anchor blood vessels, thus 
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leading metastatic cells toward the blood stream (Condeelis and Segall 2003). Once close 
to the abluminal side of the vessel, macrophages cluster on its surface to assist cancer 
cells in the intravasation process (Wyckoff, Wang et al. 2007). This localized movement 
near to vessels has been confirmed by intravital imaging of xenografted tumors 
(Gligorijevic, Kedrin et al. 2009). 
Tumor cell migration requires proteolytic destruction of the ECM to allow detachment of 
cancer cells from the basement membrane, and for migration through the stroma. 
Macrophages are strong producers of many proteases, such cathepsins, MMPs, and serin 
proteases (Egeblad and Werb 2002). Loss of cathepsin B, S and urokinase in macrophages 
inhibits metastasis formation (Almholt, Lund et al. 2005; Gocheva, Wang et al. 2010). 
Cancer is a systemic disease, and neoplastic cells in the primary tumor can influence 
metastatic outcome at distant sites. Once in the bloodstream, circulating cancer cells 
need to extravasate and seed to a new site. This steps are the most limiting in all the 
metastatic process, and tumor cells require the support of myeloid cells, which are 
mobilized and recruited in future metastatic tissues by soluble factors released by the 
primary tumor. The colonization of anatomic sites by the arrival of myeloid cells is 
referred to as the formation of the “premetastatic niche”, and interfering with its 
establishment impairs the metastatic process. Kaplan et colleagues described for the first 
time the presence of clusters formed by bone-marrow derived cells in the lungs, prior to 
the arrival of metastatic cells (Kaplan, Riba et al. 2005). These clusters accommodate 
incoming cancer cells and sustain their growth in situ. The niche-forming cells are CD11b+ 
and VEGFR1+, indicative of mononuclear phagocytic cells (Kaplan, Riba et al. 2005; 
Hiratsuka, Watanabe et al. 2006). It is not clear what is the exact function of these niches: 
it is believed that they provide sites for tumor cells to adhere and prosper, supplying 
nourishment and possibly protection from antitumor immune responses. The choice of 
the organ for the formation of the premetastatic niches is determined by tumor-released 
soluble factors, postulating that the spectrum of molecules secreted by a particular tumor 
will influence the tissues in which metastases will occur (Kaplan, Riba et al. 2005). The 
myeloid chemoattractants S100A8 and S100A9 are among the tumor-produced factors 
required for the premetastatic niche formation (Hiratsuka, Watanabe et al. 2006). Tumor 
cells can induce the recruitment of myeloid cells in premetastatic sites by also remodeling 
the ECM in distant tissues. By releasing Lysyl oxidase (LOX), breast tumor cells can 
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crosslink collagen IV in the premetastatic sites, inducing the recruitment of CD11b+ 
myeloid cells. Adherence of these cells to cross-linked collagen IV induce their secretion 
of MMP2, which cleaves collagen and enhances the extravasation of circulating tumor 
cells (Erler, Bennewith et al. 2009). 
It is not clear whether macrophages participate to the premetastatic niche formation. 
However, a population of CCR2+ metastases-associated macrophages (MAMs) were 
shown to facilitate extravasation of circulating tumor cells, and to sustain their in situ 
growth (Qian, Deng et al. 2009). MAMs origin from circulating CCR2+ inflammatory 
monocytes, which are recruited through CCL2 secreted by tumor cells and the stroma. 
Blocking of the CCL2-CCR2 chemokine axis reduces the recruitment of MAMs and impairs 
metastatic seeding (Qian, Li et al. 2011). Physical interactions have been observed 
between MAMs and tumor cells at the metastatic site, suggesting short-range 
transmission of growth and survival signals (Qian, Deng et al. 2009). 
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Developmental origin of TAMs and MDSCs 
 
Bone marrow is the source of circulating blood leukocytes. It is also where most 
terminally differentiated myeloid cells originate. Myeloid cells have a common origin in 
bone marrow-resident hematopoietic stem cells (HSCs) and develop through the process 
of  myelopoiesis, along several myeloid progenitors and differentiation pathways. This 
process is inherently governed by interaction of myeloid progenitors with the bone 
marrow stroma, which creates an organized microenvironment where trophic and 
differentiation stimuli are strictly regulated (Kiel and Morrison 2008). However, the bone 
marrow dynamically changes its myeloid output in response to external stimuli, like those 
generated by infections and other tissue homeostasis-perturbing situations. Inflamed 
tissues release soluble factors which reach the bone marrow through the blood stream 
and alter the rate and composition of myeloid cell production. Considering the myeloid 
nature of several components of the tumor microenvironment, it is not unexpected that 
tumor cells can influence myelopoiesis. The following part will first focus on the 
hematopoietic development of the mononuclear phagocyte system under steady state. 
Then the focus will shift to discuss how tumors manage to obtain the two most essential 
tumor-infiltrating myeloid populations, that is TAMs and MDSCs. 
 
Differentiation of monocytes, macrophages and dendritic cells 
Current models propose that mononuclear phagocytic cells origin from HSC-progenitors 
with myeloid-restricted differentiation potential. Successive commitment steps include 
common myeloid progenitors (CMPs), granulocyte-macrophage precursors (GMPs), and 
macrophage/DC progenitors (MDPs) (Geissmann, Manz et al. 2010). MDPs are 
proliferating cells which give rise to many subsets of macrophages and DCs but cannot 
generate granulocytes, thus representing the step in which the mononuclear phagocytic 
commitment occurs in myelopoiesis (Fogg, Sibon et al. 2006). Still within the bone 
marrow, MDPs differentiate to monocytes and to common DC precursors (CDPs). CDPs 
are proliferating cells which differentiate into plasmacytoid DCs and the precursors of 
classical DCs (pre-cDCs), but have lost the potential to generate monocytes (Liu, Victora et 
al. 2009). Pre-cDCs migrate through the blood into lymphoid tissues, where they acquire a 
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mature DC phenotype and morphology. Monocytes enter the blood and migrate into 
tissues under inflammatory conditions. Once there, they differentiate into subsets of 
macrophages and inflammatory DCs, which share many functions with classical DCs like 
the ability to process and present antigens to T cells (Geissmann, Jung et al. 2003; Auffray, 
Fogg et al. 2009; Murray and Wynn 2011). 
 
Monocytes consist of two distinct subsets 
Monocytes are immune effector cells that circulate in the blood, spleen and bone marrow 
and do not proliferate under steady state (Auffray, Sieweke et al. 2009). They can 
produce inflammatory cytokines and engulf cellular and toxic molecules. They are also 
equipped with chemokine receptors and adhesion molecules that allow them to migrate 
to inflamed tissues, where they differentiate into inflammatory DCs or macrophages 
(Serbina, Jia et al. 2008). Migration and differentiation of monocytes are likely regulated 
by the inflammatory milieu and microbial products (PAMPs). 
Monocytes can be recognized by expression of the myeloid marker CD11b and the 
monocyte/macrophage marker CSF-1 receptor (CSF-1R, also known as CD115), whose 
agonist is the macrophage colony stimulating factor (M-CSF, also known as CSF-1). M-CSF 
regulates the proliferation, survival, differentiation and motility of both monocytes and 
macrophages (Pixley and Stanley 2004). Circulating monocytes can further be divided in 
two distinct subsets. Inflammatory monocytes have high expression of the LY6C marker. 
They are termed as such because they migrate to inflamed tissues and differentiate into 
inflammatory DCs or macrophages (Geissmann, Manz et al. 2010). For example, during 
infection with Listeria monocytogenes, LY6Chigh monocytes differentiate into DCs that 
produce inflammatory mediators as TNFα, NO and ROS (Narni-Mancinelli, Campisi et al. 
2007). These cells are called TNFα and iNOS-producing dendritic cells or TipDCs; however, 
some Authors assert they can be considered just a variant of M1 macrophages (Murray 
and Wynn 2011). Ly6Chigh monocytes are also required against infection with Toxoplasma 
gondii, but in this case they differentiate into mucosal macrophages (Dunay, Damatta et 
al. 2008). The spleen harbors large numbers of LY6Chigh monocytes in the subcapsular red 
pulp that can rapidly emigrate to inflammatory sites (Swirski, Nahrendorf et al. 2009). 
Inflammatory monocytes express high levels of CCR2 and L-selectin, and respond to CCL2 
to exit the bone marrow and enter inflamed tissues (Kim, Kamada et al. 2011; Shi, Jia et 
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al. 2011). Interestingly, inflammatory monocytes are phenotypically similar to 
LY6ChighCCR2+ M-MDSCs, which migrate within tumors in response to CCL2 (Ugel, 
Peranzoni et al. 2012).  
A population of LY6Cneg monocytes is also found in the spleen, blood and bone marrow. 
These monocytes lack expression of CCR2 but have high quantities of CX3C chemokine 
receptor 1 (CX3CR1) and integrin LFA-1 on their surface. They are termed resident 
monocytes because of their longer half-life in vivo and their localization to both resting 
and inflamed tissues after adoptive transfer (Auffray, Fogg et al. 2007). Resident 
monocytes patrol the luminal side of the vascular endothelium and ideally survey 
endothelial cells and surrounding tissues for damage or infection. They also accumulate in 
the ischemic myocardium at a late phase, to promote healing through VEGF-induced 
angiogenesis and deposition of collagen (Nahrendorf, Swirski et al. 2007). The orphan 
nuclear receptor NR4A1 is required for the development of resident monocytes (Hanna, 
Carlin et al. 2011). Inflammatory monocytes have been seen to shuttle between the blood 
and bone marrow and lose their LY6C expression (Varol, Landsman et al. 2007); however, 
the hypothesis of a developmental relationship between the two monocyte subsets still 
waits a formal proof. 
 
Differentiation potential of monocyte subsets 
It is classically accepted that monocytes are plastic cells with multiple differentiation 
options, allowing them to generate macrophages and DC-like cells with several possible 
phenotypes. This concept of plasticity is largely based on the effects of cytokines on 
monocytes in vitro. The main cytokines which drive myeloid differentiation are the CSFs 
(Burgess and Metcalf 1980), molecules termed in this way according to their ability to 
drive in vitro formation of colonies comprising  mature myeloid cells from bone marrow 
precursors. G-CSF and M-CSF generate granulocytic and monocyte/macrophage colonies 
respectively, while GM-CSF generates a mixture of both colonies. Monocytes exposed in 
vitro to a combination of GM-CSF and IL-4 generate DCs, while exposure to M-CSF induces 
monocyte differentiation into macrophages (Sallusto and Lanzavecchia 1994; Zhang, 
Goncalves et al. 2008). The latter can further be stimulated in vitro with either IFN and 
LPS or IL-4 and IL-13, in order to obtain M1 and M2 macrophages, respectively (Mosser 
and Zhang 2008). GM-CSF alone is able to induce macrophage differentiation, however 
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these macrophages are not similar to those obtain with M-CSF. GM-CSF-exposed 
macrophages secrete the proinflammatory cytokines TNFα, IL-6, IL-12p70 and IL-23 
following stimulation with microbial products; these macrophages have antigen-
presenting and other DC-like capabilities. Conversely, M-CSF-exposed macrophages 
produce IL-10 and CCL2, have phagocytic functions and a more macrophage-like 
morphology (Hamilton 2008). Although reductive, it could be summarized that GM-CSF-
induced macrophages are primed toward a proinflammatory “M1-like” phenotype, while 
M-CSF-induced macrophages have an anti-inflammatory behavior which resemble M2 
polarization. To explain these observations, it has been proposed that tissue-resident 
macrophages are maintained in an anti-inflammatory status by the continuous exposure 
to M-CSF, which circulates at detectable levels under steady-state. M-CSF could have the 
function to prevent inappropriate activation of macrophages by proinflammatory signals, 
in order to avoid unwanted inflammation and tissue damage. Conversely, GM-CSF is 
detected in the blood only after perturbation of the steady-state, for example in the case 
of infections. Exposure of macrophages to increasing levels of GM-CSF and other 
proinflammatory stimuli could induce a sort of “M-CSF resistance”, where M-CSF signaling 
is reduced or cut out (Hamilton 2008). When proinflammatory stimuli gradually decrease, 
the continuous presence of M-CSF in tissues should facilitate the macrophage-mediated 
resolution of inflammation. 
Both monocyte subsets have the same differentiation behavior when stimulated in vitro. 
However, when adoptively transferred to mice carrying L. monocytogenes infection, 
resident monocytes initiate a macrophage differentiation program that resembles the 
one described for M2 macrophages (Auffray, Fogg et al. 2007). Conversely, inflammatory 
monocytes that enter the site of infection initiate a differentiation program that mimics 
the one leading to either TipDCs or M1 macrophage skeweing (Narni-Mancinelli, Campisi 
et al. 2007). These evidences seemingly contradict the notion of a general plasticity of 
monocytes and macrophages, rather suggesting a programmed evolution from different 
precursors; in vitro studies may not, however, fully recapitulate in vivo differentiation of 
mononuclear phagocytes (Geissmann, Manz et al. 2010). This stresses the need for in vivo 
studies to rigorously understand, both spatially and temporally, the differentiation and 
cell fate decisions of monocytes and macrophages, both under steady-state and 
inflammatory conditions. 
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Hematopoietic stem cell-independent origin of macrophages 
Recent findings indicate that macrophages can sometimes undergo self-renewal in tissues 
without the contribution of bone marrow-derived precursors. During helminth infection, 
macrophages were shown to proliferate in situ in response to IL-4 produced by Th2 cells 
(Jenkins, Ruckerl et al. 2011). This resulted in increased numbers of M2 effector 
macrophages, which contributed to expel the worms. The mechanism used by IL-4-
signaling to induce proliferation is not clear at the moment, but may be related to the 
regulation of the transcription factors macrophage-activating factor (MAF) and MAFB, 
which suppress proliferation in mature monocytes and macrophages (Aziz, Soucie et al. 
2009). 
A recent paper by the group of F. Geissmann has shown that the transcription factor 
myeloblastosis oncogene (MYB), which is essential for the development of the 
hematopoietic system, is dispensable for the generation of yolk sac-derived macrophages 
found in several tissues (Schulz, Gomez Perdiguero et al. 2012). These macrophages 
comprehend liver Kupffer cells, epidermal Langerhans cells and microglia, which can 
persist in adult mice independently of HSCs. The HSC-independent generation of 
macrophages requires the transcription factor PU.1, which operates also the bone 
marrow-dependent macrophage development. 
 
Transcriptional regulation of mononuclear phagocyte lineage commitments 
Lineage potentials are progressively restricted during differentiation of mononuclear 
phagocytes; this requires the selection of specific gene expression programs. In vivo 
knockout murine models have shown a role for several transcription factors, but their 
deficiency often causes broad effects in multiple cell types (Auffray, Sieweke et al. 2009). 
However, some exceptions have been found, like the Kruppel-like factor 4 (KLF4), whose 
depletion affects in vivo the generation of inflammatory monocytes (Alder, Georgantas et 
al. 2008), or the role of NR4A1 in the development of resident monocytes (Hanna, Carlin 
et al. 2011). Nevertheless, important functions in specific commitment events have been 
found for various transcription factors, despite their knockouts cause broad effects on 
many myeloid lineages in vivo. The transcription factor PU.1 is necessary for the early 
steps of myeloid lineage commitment of HSCs and its absence results in general myeloid 
deficiency (McKercher, Torbett et al. 1996). However, it has key functions during specific 
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commitment choices of the myeloid lineage diversification, in particular the macrophage-
versus-DC choice of monocytes. Generally, the balance between antagonistic 
transcription factors drives the commitment fate of myeloid progenitors. In line with this 
concept, high expression of PU.1 is required to induce DC fate in monocytes and to 
antagonize the macrophage differentiation-inducing transcription factors MAF and MAFB 
(Bakri, Sarrazin et al. 2005).  
Gain-of-function experiments have been used to determine the potential of transcription 
factors in defining the differentiation fate of myeloid progenitor cells. 
Monocyte/macrophage commitment in early myeloid progenitors is driven by ectopic 
expression of the transcription factors MAFB, MAF, early growth response 1 (EGR1), 
interferon regulatory factor 8 (IRF8), KLF4 and PU.1, while DC differentiation is induced by 
PU.1 and viral reticuloendotheliosis (v-rel) oncogene homolog B (RelB) (Geissmann, Manz 
et al. 2010). It is important to note that lineage commitments ground on the coupling of 
these transcription factors with cytokine receptor signaling. In the case of the M-CSF-
dependent signaling, which is pivotal for monocyte/macrophage commitment and 
differentiation, it has been established that MAFB limits M-CSF signals and inhibits PU.1 
activation in HSCs (Sarrazin, Mossadegh-Keller et al. 2009), while MAFB and MAF together 
inhibit M-CSF-instructed proliferative signals in mature monocytes and macrophages, 
thus assuring their withdrawal from cell cycle (Aziz, Soucie et al. 2009). 
 
Monocyte/macrophage differentiation mainly depends on the M-CSF-induced signaling 
pathways and requires autophagy 
M-CSF-signaling is the main regulator of monocytes and macrophages developments. 
Mice that are homozygous for a null allele of the Csf1 gene are termed osteopetrotic 
(Csf1op/op), due to the negative effects on the bone reabsorption consequent to a strong 
decrease in osteoclasts (Wiktor-Jedrzejczak, Bartocci et al. 1990). These mice also have 
developmental defects in many tissues, due to a reduction of resident macrophages. 
Although GM-CSF induces macrophage differentiation, GM-CSF-deficient mice have only 
an isolated lung lesion reminiscent of pulmonary alveolar proteinosis, index of impaired 
scavenger activity by alveolar macrophages (Dranoff, Crawford et al. 1994). The apparent 
GM-CSF-independency of most macrophages for their development in vivo highlights the 
importance of M-CSF as the main growth factor for monocytes and macrophages. It 
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should be noted that monocytes secrete M-CSF when they are stimulated with GM-CSF in 
vitro, thus suggesting that GM-CSF-induced macrophage differentiation could actually be 
M-CSF-dependent (Chomarat, Banchereau et al. 2000). 
CSF-1R (CD115) is a lineage specific marker and is expressed on MDPs, monocytes and 
macrophages (Geissmann, Manz et al. 2010). It is a receptor tyrosine kinase, whose 
stimulation by M-CSF induces strong tyrosine phosphorylation of intracellular proteins 
(Pixley and Stanley 2004). CSF-1R activation also results in increased size and number of 
complexes containing phosphotyrosine proteins, which include cytoskeletal and 
cytoskeleton-interacting molecules (Yeung and Stanley 2003). Through its receptor, M-
CSF controls the survival, proliferation, differentiation and motility of macrophages. The 
CSF-1R downstream pathways are, however, poorly understood, in particular those 
controlling cell growth and differentiation programs (Pixley and Stanley 2004). Moreover, 
we have a poor knowledge of the cellular processes that sustain macrophage 
differentiation and how these processes are governed by the CSF-1R downstream signals. 
Interestingly, the M-CSF-dependent differentiation of macrophages was recently linked to 
the process of autophagy (Jacquel, Obba et al. 2012; Zhang, Morgan et al. 2012).  
Autophagy allows cells to degrade cytoplasmic material in the lysosome, in order to 
produce new building blocks and energy for cellular renovation and homeostasis. 
Autophagy is classically seen as an adaptive metabolic response to cell starvation: by 
recycling their amino acids, autophagic cells can build new proteins and readapt their 
proteome to new environmental conditions (Mizushima and Komatsu 2011). Nitrogen 
starvation induces the highest levels of autophagy in yeasts and mammalian cells; when 
local levels of amino acids are restored, the serine/threonine protein kinase mammalian 
target of rapamycin complex 1 (mTORC1) is activated and this determines termination of 
autophagy (Yu, McPhee et al. 2010). During starvation, recycled amino acids are mainly 
used to synthetize vacuolar/lysosomal enzymes, respiratory chain proteins, antioxidant 
enzymes, and proteins involved in pathways of amino acid biosynthesis (Suzuki, Onodera 
et al. 2011). These proteins have the main purpose to maintain the functionality of 
mitochondria: autophagy-deficient yeast cells are not able to sustain their respiratory 
functions, and as a result, high levels of ROS accumulate, compromising mitochondrial 
DNA integrity and cell survival (Suzuki, Onodera et al. 2011). Fresh amino acids are also 
converted in intermediates of the tricarboxylic acid cycle, thus fueling ATP production and 
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protein synthesis in spite of nutrient starvation (Guo, Chen et al. 2011). Nevertheless, 
different types of cells also display basal autophagic activity under nutrient-rich 
conditions, indicating other roles for autophagy that are not strictly related to metabolic 
needs. These include the quality check of organelles and intracellular proteins, and the 
recycling of unnecessary material during development and renovation of tissues 
(Mizushima and Komatsu 2011). These functions are based on the ability of cells to 
selectively target specific proteins and organelles to the autophagic machinery, thus 
exploiting “selective autophagy”. 
Two independent research groups reported that monocytes activate autophagy after 
either M-CSF or GM-CSF in vitro stimulation. This was required to undergo macrophage 
differentiation, as assessed by genetic and pharmacological approaches (Jacquel, Obba et 
al. 2012; Zhang, Morgan et al. 2012). In the study by Zhang et colleagues, blocking 
autophagy had a detrimental effect on monocyte survival; however, the group of Jacquel 
reported that autophagy inhibition impaired the maturation of macrophages without 
evident effects on monocyte viability. This discrepancy could be explained by the use of 
different stimuli (either GM-CSF or M-CSF) to trigger macrophage differentiation, and by 
the choice of different approaches to inhibit autophagy. Interestingly, both reports 
indicate that autophagy impairment also compromise macrophage functionality, as 
assessed by measurement of cytokine production and phagocytic functions. Zhang et 
colleagues reported that induction of autophagy by GM-CSF required the enzymatic 
activity of c-jun N-terminal kinase 1 (JNK1). Activated JNK1 induces phosphorylation of B-
cell lymphoma 2 (Bcl2), allowing dissociation of the Bcl2-Beclin 1 complex and consequent 
Beclin 1-mediated triggering of autophagy (Wei, Pattingre et al. 2008). Interesting, Bcl2 
has anti-apoptotic functions, which are exploited by physical interaction with the pro-
apoptotic protein BCL2-associated X protein Bax (Pope 2002). Dissociation from Beclin 1 
could allow Bcl2 to interact with Bax and inhibit loss of mitochondrial transmembrane 
potential, thus explaining the anti-apoptotic protective effect of autophagy on 
monocytes. 
 
Description of the autophagy process 
The autophagy process is based on the function of a short-lived organelle called the 
“autophagosome”. An isolation membrane, termed “phagophore”, sequesters a small 
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portion of the cytoplasm together with its content, to form the autophagosome. 
Autophagosomes fuse with late endosomes or mature lysosomes in order to degrade 
their cargo (Mizushima and Komatsu 2011). A major concern in our understanding of 
autophagy is where the autophagosome membrane comes from. So far, the main 
candidate has been the endoplasmic reticulum (ER), because autophagosomes are usually 
generated in close proximity to it (Mizushima, Yoshimori et al. 2011). However, several 
studies have suggested that the Golgi complex, the mitochondria, and the plasma 
membrane also contribute to autophagosome formation (Hailey, Rambold et al. 2010; 
Ravikumar, Moreau et al. 2010; Tooze and Yoshimori 2010).  
Mechanically, the autophagy process is conducted by the protein products of several 
genes originally identified in yeast, which have been called “autophagy-related” (ATG) 
genes (Nakatogawa, Suzuki et al. 2009). Among the 35 Atg proteins thus far identified in 
yeast, Atg1-10, 12-14, and 18 are the “core Atg proteins”. These proteins, together with 
Atg17, 29, and 31, are necessary for autophagosome formation (Nakatogawa, Suzuki et al. 
2009), and are highly conserved in other eukaryotes. In mammals, autophagy is initiated 
by the Atg1/Unc-51-like Kinase (Atg1/ULK) complex, which comprises ULK1, mAtg13, focal 
adhesion kinase family interacting protein of 200 kDa (FIP200) and Atg101 (Mizushima, 
Yoshimori et al. 2011). This complex is present in the cytosol, but it relocates to some 
domains of the ER upon autophagy induction, possibly forming pre-autophagosomal (PAS) 
structures (Itakura and Mizushima 2010). The  function of the ULK1 complex is to organize 
PAS by ULK1-mediated phosphorylation of several downstream autophagy-related 
proteins. The main target of its kinase activity is the class III phosphatidylinositol (PtdIns) 
3-kinase (PI3K) complex, which includes Beclin 1, Atg14(L)/Barkor, vacuolar protein 
sorting 15 (Vps15), Vps34, and autophagy/beclin 1 regulator 1 (AMBRA1). The PI3K 
complex is localized to the ER membrane thanks to Atg14(L), and this requires 
phosphorylation of the latter by the ULK1 complex (Matsunaga, Morita et al. 2010). The 
PI3K complex produces PtdIns(3)P on the membrane of the ER; this allows the 
recruitment of FYVE-containing protein 1 (DFCP1) through its PtdIns(3)-binding FYVE 
domain (Axe, Walker et al. 2008). During autophagy, DFCP1 concentrates in spots on the 
ER; these spots provide a platform for the expansion of the phagophore (Axe, Walker et 
al. 2008). “Omegasome” is the name of the -like shaped PtdIns(3)P-enriched ER region 
which is specific to autophagosome biogenesis (Mizushima, Yoshimori et al. 2011). 
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Two ubiquitin-like conjugation systems are required for the expansion and closure of the 
isolation membrane. The two conjugates, Atg12-Atg5 and microtubule-associated protein 
1 light chain 3-phospatidyl ethanolamine (LC3-PE; also known as LC3-II) are good markers 
for the detection of autophagy-related membrane structures and autophagosomes 
(Suzuki, Kubota et al. 2007). Atg12-Atg5 interacts with Atg16L1 to create a complex that is 
necessary for LC3-PE formation (Hanada, Noda et al. 2007). The LC3 precursor (LC3-I) is 
cleaved by the cysteine protease Atg4; the resulting C-terminal glycine-exposed form of 
LC3 is activated by the E1 enzyme, transferred to the E2 enzyme, and finally covalently 
linked to an amino group of PE (Ichimura, Kirisako et al. 2000). LC3-PE has membrane 
tethering and hemifusion activities (Nakatogawa, Ichimura et al. 2007), which are 
required for expansion of the phagophore. Another important function of LC3 is to serve 
as receptor for selective autophagy. LC3 recognizes the WXXL-like sequence in substrate 
proteins or adaptors like sequestosome 1 (SQSTM1/p62), which is selectively 
incorporated into autophagosomes (Johansen and Lamark 2011). The protein p62 has an 
ubiquitin-associated domain through which it can mediate sequestration of ubiquitinated 
proteins into autophagosomes. Impairment of autophagy leads to intracellular 
accumulation of p62 and the formation of large p62-ubiquitin aggregates (Komatsu, 
Kurokawa et al. 2010). 
 
Abnormal myelopoiesis in cancer: development of MDSCs 
Immature myeloid cells accumulate in the blood and lymphoid organs of tumor-bearing 
hosts (Bronte, Chappell et al. 1999; Almand, Resser et al. 2000; Bronte, Apolloni et al. 
2000; Gabrilovich, Velders et al. 2001). As discussed above, these cells initiate highly 
immune suppressive programs when triggered by activation of a cell-mediated immune 
response, thus becoming MDSCs. They also accumulate in patients with chronic 
infections, trauma, and autoimmune diseases, suggesting that MDSCs represent an 
emergency system that hampers excessive immune activation (Gabrilovich, Ostrand-
Rosenberg et al. 2012). Cancer cells induce the development of MDSCs by releasing 
several tumor-derived soluble factors (TSFs) that directly act on the HSC (Gabrilovich, 
Ostrand-Rosenberg et al. 2012). TSFs not only augment the production of immature 
myeloid cells in the bone marrow, but also determine a blockade of their maturation skills 
(Bronte, Chappell et al. 1999; Bronte, Apolloni et al. 2000; Bronte, Serafini et al. 2001). 
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GM-CSF, G-CSF, M-CSF, stem cell factor (SCF), VEGF and IL-3 are well-known TSFs which 
alter normal myelopoiesis during cancer (Bronte, Serafini et al. 2001; Gabrilovich 2004; 
Serafini, Carbley et al. 2004). 
So far the GM-CSF has been shown to have a fundamental action on MDSC development. 
GM-CSF is one of the most common cytokines secreted by tumors, and its chronic 
production impairs the antigen-specific responsiveness of CD8+ CTLs (Bronte, Chappell et 
al. 1999). Knockdown of GM-CSF in tumor cells inhibits in vivo the recruitment of M-
MDSCs, thus resulting in the interruption of tumor-induced tolerance (Dolcetti, Peranzoni 
et al. 2010). Recently, the prevalent role of GM-CSF in inducing tumor-associated immune 
dysfunction has been confirmed using spontaneous models of pancreatic carcinoma. In 
early stage neoplastic lesions, the oncogene Kras(G12D) activates GM-CSF secretion in 
pancreatic ductal epithelial cells (Pylayeva-Gupta, Lee et al. 2012). The suppression of 
GM-CSF production in tumor cells has a negative impact on the recruitment of 
CD11b+GR1+ MDSCs, resulting in CD8+ CTL-dependent inhibition of tumor growth (Bayne, 
Beatty et al. 2012; Pylayeva-Gupta, Lee et al. 2012). Importantly, the Authors found that 
human pancreatic carcinomas abundantly secrete GM-CSF in vivo. GM-CSF is often used 
as an adjuvant in antitumor immunotherapies because it stimulates DC differentiation; 
however, excessive administration of this cytokine exacerbates immune suppression in 
vivo, thus mining the therapeutic outcome of antitumor vaccination (Serafini, Carbley et 
al. 2004). 
The transcription factor STAT3 has been implicated as the main mediator of TSF-induced 
arrest of myeloid maturation. The normal differentiation of early myeloid progenitor cells 
require STAT3 activation, which progressively decreases during the late stages of DC 
differentiation (Smithgall, Briggs et al. 2000; Nefedova, Huang et al. 2004). However, 
STAT3 is found constitutively activated in MDSCs (Nefedova, Huang et al. 2004), and its 
activation blocks the differentiation of CD11c+CD86+ mature DCs (Wang, Niu et al. 2004). 
Persistent STAT3 activation is induced in myeloid progenitor cells by in vitro treatment 
with TSFs, and this activation prevents DC maturation induced by appropriate stimuli 
(Nefedova, Huang et al. 2004). Similar results are obtained when immature myeloid cells 
from tumor-bearing mice are adoptively transferred in tumor-free versus tumor-bearing 
littermates (Kusmartsev and Gabrilovich 2003). STAT3 induces cell proliferation and 
prevents apoptosis  by upregulating the antiapoptotic proteins BCL-XL and survivin, and 
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the proproliferative proteins MYC and cyclin D1, thus sustaining the expansion of MDSCs 
(Yu, Pardoll et al. 2009). Moreover, STAT3 inhibits DC differentiation by upregulating the 
calcium-binding proinflammatory proteins S100A8 and S100A9, and by downregulating 
protein kinase Cβ isoform II (Cheng, Corzo et al. 2008; Farren, Carlson et al. 2010). 
The transcription factor CAAT-enhancer-binding protein-β (C/EBPβ) is also required for 
generation of M-MDSCs and acquisition of their immune suppressive functions (Marigo, 
Bosio et al. 2010). The C/EBP family of transcription factors is tightly regulated during 
macrophage and granulocyte differentiation (Rosenbauer and Tenen 2007). In normal 
individuals, C/EBPβ controls emergency granulopoiesis (Hirai, Zhang et al. 2006). C/EBPβ 
mediates the generation of M-MDSCs induced  by GM-CSF and IL-6, both of which are 
required for complete acquisition of the MDSC immune suppressive program (Marigo, 
Bosio et al. 2010). C/EBPβ expression is under the control of STAT3 (Zhang, Nguyen-
Jackson et al. 2010), and individual knockouts of these transcription factors have similar 
benefic results on the accumulation of mature myeloid cells in tumor-bearing mice 
(Nefedova, Huang et al. 2004; Wang, Niu et al. 2004; Marigo, Bosio et al. 2010). 
Interestingly, both STAT3 and C/EBPβ co-regulate MYC expression by modulating, at the 
promoter level, the dissociation of the Myc repressor C/EBPα (Zhang, Nguyen-Jackson et 
al. 2010). Considering that C/EBPα regulates granulopoiesis under steady-state 
conditions, it seems that both STAT3 and C/EBPβ cooperate to promote myeloid lineage 
commitments required during stress-responses, including cancer. 
 
Origin of TAMs 
Understanding the mechanisms governing TAM differentiation is of great importance for 
developing new therapeutic strategies. Oddly, there are only few reports which have 
focused on the origin and in situ differentiation of tumor-infiltrating macrophages. A 
relatively recent report by the group of Ginderachter showed that, in two different 
transplantable models of lung and mammary carcinomas, TAMs originated by circulating 
Ly6Chigh inflammatory monocytes (Movahedi, Laoui et al. 2010). Monocytes were shown 
to undergo progressive phenotypic changes during intratumoral differentiation, finally 
becoming Ly6Clow/negLy6GnegF4/80high macrophages. In the same report, Ly6Cneg resident 
monocytes were not shown to migrate to primary tumors, thus excluding their 
contribution to TAM replenishment (Movahedi, Laoui et al. 2010). However, this is in 
45 
 
contrast with a recent paper by Qian and colleagues showing that in a spontaneous 
model of metastatic mammary carcinoma, resident monocytes preferentially accumulate 
into the primary tumor, while inflammatory monocytes are found to migrate to 
metastatic sites (Qian, Li et al. 2011). This discrepancy could be ascribed to the use of 
different kind of tumor models (transplantable versus spontaneous one); however, the 
exact contribution of both monocyte subsets to TAM replenishment need to be further 
clarified. 
Another subject of discussion is the exact relationship between MDSCs and TAMs. It has 
been proposed that MDSCs could be the precursors of TAMs (Sica, Schioppa et al. 2006); 
a direct proof was given by Corzo and colleagues, showing that purified splenic 
CD11b+GR1+ MDSCs differentiate in CD11b+GR1negF4/80+ macrophages when injected in 
ascites induced by the EL4 tumor (Corzo, Condamine et al. 2010). The authors found that 
the same differentiation process could be induced by culturing MDSCs under hypoxic 
conditions and that the transcription factor HIF1α was responsible for it. Interestingly, 
hypoxia was able to induce the HIF1α-mediated upregulation of both iNOS and ARG1 in 
MDSC-derived macrophages without the need for  macrophage polarization stimuli 
(Corzo, Condamine et al. 2010). This evidence reflects the MDSC ability to co-express 
these two enzymes, which are mutually exclusive when induced in macrophages 
(Gabrilovich, Ostrand-Rosenberg et al. 2012).  
It should be noted that Corzo and co-workers used the CD11b and GR1 markers to isolate 
splenic MDSCs; unfortunately, these markers alone are not sufficient to discriminate 
these cells from other related myeloid subsets, like inflammatory monocytes. This issue 
raises the question whether the true source of macrophage precursors were transferred 
MDSCs or other cellular contaminants during in vivo differentiation experiments. 
Nevertheless, this paper highlights the regulatory potential of hypoxia in shaping the 
differentiation and behavior of TAMs. Consistent with this notion, Movahedi and 
colleagues found that M2 TAMs were enriched in hypoxic tumor areas (Movahedi, Laoui 
et al. 2010). HIF1α is constitutively expressed in macrophages, and its transcriptional 
activity modulates CCL2- and endothelin-mediated recruitment of macrophages  to 
hypoxic regions of the tumor (Murdoch, Muthana et al. 2008). In a mouse model of 
spontaneous mammary carcinoma, HIF1α increased the expression of iNOS and ARG1 
when macrophages were stimulated with either TH1 or TH2 citokines, and HIF1α 
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deficiency impaired the suppressive ability of TAMs (Doedens, Stockmann et al. 2010). 
This transcription factor also regulates the expression of a large panel of genes associated 
with angiogenesis, including VEGF (Murdoch, Muthana et al. 2008). All these findings 
highlight the importance of local oxygen tension in regulating macrophage differentiation 
and behavior. Proteins of the ECM have also been implicated in controlling macrophage 
protumoral activities. For example, the proteoglycan versican, which is secreted by Lewis 
lung carcinoma cells, stimulates metastasis through TLR2 signaling in macrophages (Kim, 
Takahashi et al. 2009). It is likely that both environmental factors and structural 
components of the tumor stroma, in concert with cytokines that promote macrophage 
differentiation (like M-CSF and IL-6), altogether regulate TAM development and functions; 
however, the underlying mechanisms still remain largely unresolved. 
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Aim of the present study 
 
At first sight, cancer seems a chaotic environment in which neoplastic cells proliferate 
without control, generating a disorganized mass that compromises nearby tissues. 
However, the arguments discussed so far indicate that tumors are highly organized 
systems, where cancer cells and normal cells strictly cooperate to sustain tumor growth 
and subvert host defenses. Tumor-infiltrating myeloid cells are of capital importance in 
this scenario, and for this reason tumor-myeloid cell interactions are the focus of intense 
research efforts. To obtain starting cues about new relevant molecular pathways acting in 
tumor-infiltrating myeloid cells, we performed gene expression analysis in purified 
CD11b+ intratumoral myeloid cells isolated from different transplantable mouse tumor 
models. The choice of these models was made in order to cover different genetic 
backgrounds and different tumor histologies. Using Affimetrix® high-density gene 
expression arrays, we analyzed the transcriptome of CD11b+ tumor-infiltrating myeloid 
cells, comparing them to splenic CD11b+ myeloid cells purified from healthy mice as 
baseline control. The comparison was operated matching the relative genetic 
backgrounds. Among the most upregulated genes, we were particularly interested in the 
disabled homolog 2, mitogen-responsive phosphoprotein (Dab2) gene. Fold-change 
results for this gene are shown in table 1. 
 
tumor model histology genetic background relative fold-change 
4T1 mammary carcinoma BALB/c 63.83 
C26GM colon carcinoma BALB/c 53.82 
MCA203 fibrosarcoma C57Bl/6 50.22 
EL4 thymoma C57Bl/6 33.02 
Table 1. Relative fold-changes of Dab2 gene expression in tumor-infiltrating CD11b+ 
myeloid cells isolated from different tumor models. 
 
The DAB2 protein is a molecular adaptor which participates to endocytosis and signal 
transduction pathways. Its main function is to link membrane receptors with clathrin 
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assemblies, allowing selective clathrin-mediated endocytosis of transmembrane proteins 
(Maurer and Cooper 2006). The vesicular trafficking has the important function to 
distribute and organize the protein content of the plasma membrane, allowing the cell to 
spatially react to external stimuli. We think that this process is of key-importance within 
the tumor microenvironment, where complex cell-to-cell interactions occur and oriented 
stimuli are released. Many of the processes we described above require cells to obtain 
spatial organization of their surface receptors and intracellular complexes. Interestingly, 
DAB2 regulates macrophage adhesion and cell spreading, and it is phosphorylated 
following M-CSF stimulation (Xu, Yang et al. 1995; Rosenbauer, Kallies et al. 2002). In the 
present study, we have characterized DAB2 expression in myeloid cells during tumor 
progression, and we have unclosed a novel function for this protein in the development 
and protumoral activities of myeloid cells. 
 
The disabled homolog 2, mitogen-responsive phosphoprotein 
The DAB2 protein was initially discovered in Drosophila Melanogaster, but human and 
mouse homologs have been characterized. It is a phosphoprotein with an actin-binding, 
N-terminal domain, a central domain with a high degree of similarity to the Drosophila 
disabled gene product, and a proline/serine-rich C-terminal domain with binding sites for 
SH3-domains (Xu, Yang et al. 1995). Two isoforms of DAB2 exist, with a molecular weight 
of 96 and 67 kilodaltons; these isoforms are generated through alternative splicing. DAB2 
was initially characterized in a macrophage cell line for its phosphorylation following 
exposure to the M-CSF cytokine (Xu, Yang et al. 1995). The protein has shown to have 
several functions, most of which are summarized in its role as “surface positioning gene” 
(Yang, Cai et al. 2007). DAB2 acts as an adaptor/linker protein between the plasma 
membrane receptors and the machinery responsible for the formation of the clathrin-
coated pits; this allows the clathrin-dependent endocytosis and the consequent 
internalization of several surface receptors. Combined with directional mechanisms of 
esocytosis, it also "concentrate” the proteins into specific sides of the cell membrane, 
thus contrasting their spontaneous diffusion in the phospholipidic bilayer (Spudich, 
Chibalina et al. 2007; Chetrit, Ziv et al. 2009).  These functions allow DAB2 to participate 
in processes like the spatial organization of epithelial cells in tissues (Yang, Cai et al. 
2007), the contact-dependent inhibition of the cellular growth in tumor cells (Fazili, Sun 
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et al. 1999), the cellular adhesion to the extracellular matrix, and the cellular migration 
and spreading (Rosenbauer, Kallies et al. 2002; Teckchandani, Toida et al. 2009). 
Moreover, DAB2 can act as an adaptor protein in several signal transduction pathways, in 
particular the WNT and TGF-β ones (Hocevar EMBO J 2003; Prunier J Biol Chem 2005). 
What we know about the endocytic properties of DAB2 are mainly based on the studies 
about the p96 isoform. The phosphotyrosine-binding (PTB) domain binds peptides 
containing the sequence FXN-PXY (Morris and Cooper 2001). This core sequence is found 
in the intracellular domains of several membrane receptors, and is important for their 
internalization. The low-density lipoprotein receptor (LDLR) family is a well-known DAB2-
interacting protein (Morris and Cooper 2001; Maurer and Cooper 2006). DAB2 transiently 
co-localizes with LDLR in clathrin-coated pits, but it is not present in endosomes and 
lysosomes (Morris and Cooper 2001). DAB2 induces clathrin assemblies at the plasma 
membrane, whose formation recruits additional endocytic proteins like adaptor protein 2 
(AP2). To achieve this effect, DAB2 requires a functional PTB domain, the ability to bind 
phospholipids, and a protein sequence that is present in p96, but not p67 (Chetrit, Ziv et 
al. 2009). This sequence contains both clathrin- and adaptor protein 2 (AP2)-binding 
motifs. Interaction of DAB2 with phospholipids is mediated by an evolutionarily 
conserved poly-lysine stretch, which precedes the PTB domain and interacts with 
negatively charged phosphoinositides. This interaction, which allows recruitment of DAB2 
at the inner leaflet of the plasma membrane, can be regulated by phosphorylation of 
Ser24 near the poly-lysine stretch (Huang, Cheng et al. 2004; Chetrit, Ziv et al. 2009). This 
phosphorylation has either positive or negative effects on DAB2 function depending on 
the cellular context (Rosenbauer, Kallies et al. 2002; Chetrit, Ziv et al. 2009; Chetrit, 
Barzilay et al. 2010). 
Intracellular transport of clathrin-coated vesicles requires myosin VI; this protein is the 
only known molecular entity that moves toward the minus ends of actin filaments 
(Morris, Arden et al. 2002). The cargo-binding domain of myosin VI interacts with the C-
terminus region of DAB2 (Morris, Arden et al. 2002; Yu, Feng et al. 2009). By this way, 
DAB2 acts as a molecular adaptor between myosin VI and clathrin, allowing the trafficking 
of clathrin-coated vesicles away from the plasma membrane into the cell (Spudich, 
Chibalina et al. 2007). 
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DAB2 has been shown to interact with several integrins (Huang, Cheng et al. 2004; Chao 
and Kunz 2009; Teckchandani, Toida et al. 2009). Cell migration is based on the forming of 
new focal adhesion contacts at the front of the cell. Integrins are cell surface receptors for 
various ECM components, with different combinations of integrin α and β subunits 
conferring ECM ligand specificity (Hynes 1992). Binding to both the ECM and cytoskeleton 
induces the clustering of active integrins into structures known as focal complexes or 
adhesions, from which signals are generated to regulate cellular responses. Conversely, 
unbound integrins are free to diffuse in the plane of the membrane (Carman and Springer 
2003). Cell migration requires active focal adhesion disassembly and integrin recycling, in 
order to allow new contacts to form near the front of the cell (Jones, Caswell et al. 2006). 
DAB2-mediated endocytosis of inactive integrins mediates their transport toward the 
leading edge of the cell movement, allowing the formation of new focal adhesion 
contacts (Teckchandani, Toida et al. 2009). 
Little is known about the functions of the p67 isoform. DAB2 is expressed in the visceral 
endoderm of mice embryos, and is required for uptake and internalization of megalin, its 
co-receptor cubilin, and a cubilin ligand, transferrin (Maurer and Cooper 2005). Prior to 
placental formation, transport across the visceral endoderm is the only way by which 
maternal proteins are transferred to the developing embryo. Dab2 knockout embryos 
arrest their development and they die prior to gastrulation (Morris, Tallquist et al. 2002). 
p96 expression is sufficient to fully rescue endocytosis in the visceral endoderm, thus 
allowing embryo development. Conversely, p67 only partially rescues endocytosis, and 
half of p67 knockin embryos are lost between E10.5 and P1 (Maurer and Cooper 2005). As 
discussed before, p67 lacks the exon encoding for the AP2- and clathrin-binding region, 
which conversely is present in p96. Nevertheless, it has been reported that p67 shows 
nuclear localization following treatment of fibroblast F9 cells with retinoic acid (Cho, Jeon 
et al. 2000). Once in the nucleus, p67 interacts with mDab2-interacting protein (mDIP), 
and can act as a transcriptional activator. However, the significance of this transcriptional 
activity in physiologic contexts has not been explored. 
There is only one report about DAB2 functions in myeloid cells. Rosenbauer and 
colleagues found that DAB2 is expressed in bone marrow-derived macrophages and 
required for cell adhesion and spreading (Rosenbauer, Kallies et al. 2002). DAB2 was 
found to regulate macrophage adhesion to laminin and collagen IV, two components of 
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the ECM. Cell adhesion to the substrate induced DAB2 phosphorylation and its 
translocation from the cytosol to the cytoskeletal fraction. Moreover, the Dab2 promoter 
was found to be recognized by the transcription factors IRF8 and PU.1; activation of IRF8 
by stimulation with IFN resulted in strong reduction of DAB2 expression. 
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Materials and methods 
 
Mice  
Eight-weeks-old C57BL/6 (H-2b), BALB/c (H-2d) and congenic CD45.1 (Ly5.1+) mice were 
purchased from Charles River Laboratories. OT-1 transgenic mice in C57BL/6 background 
(C57Bl/6-Tg(TCRαTCRβ))1100mjb), which bear a Vα2Vβ5.1-5.2 H2Kb restricted-TCR 
specific for ovalbumine peptide OVA257-264 on CD8+ T lymphocytes, were purchased from 
Charles River Laboratories. Tie2cre+/+ and Dab2flox/flox mice were a gift from P.J. Murray 
(Department of Immunology, St. Jude Children’s Research Hospital, Memphis, 
Tennessee). For simplicity, in this thesis Dab2flox/flox;Tie2cre+/-mice were named Dab2-/- 
mice. Animal care and experiments were approved by the institutional review board of 
Istituto Oncologico Veneto. All mice were maintained under specific pathogen-free 
conditions in the animal facilities of the Istituto Oncologico Veneto. Mice were inoculated 
s.c. on the left flank with tumor cells, and tumor growth was monitored every 2 days 
using a digital caliper. 
 
Cell lines  
MBL-2 lymphoma, MCA203 fibrosarcoma, EL4 thymoma and Lewis Lung carcinoma (LLC) 
cell lines are derived from C57BL/6 mice (aplotype H-2b). 4T1 mammary carcinoma and 
C26 colon carcinoma cell lines are derived from BALB/c mice (aplotype H-2d). C26-GM cell 
line was derived from C26 colon carcinoma cells genetically engineered to release GM-
CSF (Bronte, Serafini et al. 2003). This cell line was cultured in complete medium 
supplemented with geneticin antibiotic at concentration of 0.8 mg/ml. MCA-MN, a 
C57Bl/6 primary cell line of fibrosarcoma that spontaneously forms metastasis in lungs, 
was a gift of Antonio Sica (Istituto Humanitas, Milan, Italy). All cell lines were cultured in 
DMEM 10% FBS supplemented with 2mM L-glutammine, 10 mM HEPES, 20 μM 2β-ME, 
150 U/ml streptomycin, 200 U/ml penicillin. 
To generate the GFP-expressing LLC/F4 cell line, LLC cells were plated in 24 well-plates 
and allowed to grow until 80% of confluence. Cells were then exposed overnight to 
supernatants from 293T cells transfected with the GFP-reporter lentiviral vector, and 
finally cloned by limiting dilution. 
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MCA203 and EL4 cells were injected s.c. at the dose of 1x106 and 0.5x106 cells/mouse, 
respectively. C26-GM cells were injected in the inguinal fold at the dose of 0.5x106 
cells/mouse. 4T1 and LLC-GFP cells were injected s.c. at the dose of 0.5x106 and 2x106 
cells/mouse, respectively. MCA-MN were injected intra-muscle at the dose of 1x105 
cells/mouse. 
 
Cytokines and synthetic peptides  
Recombinant murine GM-CSF (100 ng/ml final concentration) and M-CSF (100 ng/ml final 
concentration) were purchased from Peprotech Inc. OVA257-264 (SIINFEKL) aplotype H-2b-
restricted peptide was synthetized by JPT. The lyophilized peptide was resuspended in 
DMSO (Sigma-Aldrich) and stored at –20°C until used. 
 
Organ cryoconservation and slice preparation  
Mice were euthanized and organs were explanted. Immediately after removal, organs 
were fixed in 3.7% formaldehyde for 3 hours at 4°C. After fixation, organs were 
dehydrated by solutions with increasing sucrose concentration for some days (PBS 20% 
sucrose and PBS 30% sucrose). Organs were included when they sunk to the bottom of 
the tubes. After dehydration, organs were included in optimal cutting medium (OCT), 
frozen on liquid nitrogen vapors and stored at -80°C. Frozen organs were cut with a 
cryostat (Leica) in 10 μm-thick slices, which were stored at room temperature.  
 
Immunofluorescence staining  
Organ slices were rehydrated in PBS for at least 10 minutes. Samples were fixed 5 
minutes in 3.7% formaldehyde at RT and washed; unspecific binding site were blocked 
with PBS 10% FBS 0.02% tween20 (blocking solution), and primary antibodies were 
incubated O.N. at 4°C in blocking solution. Slices were washed 3 times for 8’ in PBS 0.02% 
tween20 and conjugated secondary antibodies were added and incubated for 2 hours at 
37°C or O.N at 4°C. Slices were washed 3 times for 8’ in PBS 0.01% tween20 and once in 
PBS. Nuclear staining was performed with DAPI (Invitrogen) for 10 minutes at RT. Slices 
were mounted with ProLong® Gold Antifade Reagent (Invitrogen) and analyzed with a 
Leica confocal microscopy. The primary antibodies used were rat anti-mouse CD11b (BD 
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biosciences) and rabbit anti-mouse DAB2 H-110 (Santa Cruz Biotechnology, Inc.). 
Secondary antibodies were all purchased from Jackson Immune Research. 
 
Immunoblot 
Cells were collected and rinsed once in PBS, then immediately frozen in liquid nitrogen. 
Samples were dissolved in Laemmli buffer and denatured for 10 min at 100°C. Samples 
were electrophoretically separated on a 8-15% SDS-PAGE gel and transferred onto 
Immobilon P membranes (Millipore). Rabbit anti-mouse ARG1, anti-mouse NOS2 and 
anti-mouse DAB2 H-110 antibodies were purchased from Santa Cruz Biotechnology, Inc. 
Rabbit anti-mouse p62/SQTM1 and anti-mouse LC3 antibodies were purchased from 
Sigma-Aldrich. Secondary HRP-conjugated anti-rabbit antibody was purchased from GE 
Healthcare. 
 
Total RNA purification and Real-time PCR 
Total RNA was extracted by TRIzol (Invitrogen) from CD11b+Ly6G/C-F4/80+ sorted 
macrophages, according to the manufacturer’s instructions with minor modifications. The 
quality and quantity of RNA samples were determined by Agilent RNA 6000 Nano Chip 
(Agilent Technologies). cDNA from purified total RNA was produced by SuperScript II 
reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. Five 
nanograms of template cDNA was used in TaqMan real-time PCR (TaqMan Gene 
Expression Assay; 2 minutes at 50°C, 10 minutes at 95°C, 15 seconds at 95°C, 1 minute at 
60°C, for 45 cycles) performed on an ABI PRISM 7700 (Applied Biosystems). Inventoried 
Taqman probes for genes of interest were purchased by Applied Biosystems. 
 
Spleen and tumor disaggregation  
Mice were euthanized and spleens and tumors were collected. Spleens were 
mechanically disaggregated and filtered with nylon mesh filter. Splenocytes were 
centrifuged and red blood cells were lysed with a hypotonic solution. Tumors were cut in 
small pieces with a scissor; pieces were covered with a digestive solution composed of 
collagenase IV (1 mg/ml) hyaluronidase (0.1 mg/ml) and DNase (0.03 KU/ml) and 
incubated at 37°C; every 10 minutes tumors were mechanically disaggregated using a 5 
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ml pipette. After 1 hour, cells were collected and washed in complete medium twice to 
remove all digestive solution.  
 
Immunomagnetic sorting  
Total CD11b+ cells were isolated from the tumor mass through an anti-CD11b antibody 
conjugated with magnetic microbeads (Miltenyi Biotec). 1x108 cells were resuspended in 
900 μl sorting buffer (PBS 1X, 0.5% BSA, 2mM EDTA) and 100 μl anti-CD11b microbeads 
were added. Samples were incubated at 4°C for 15’ and washed with sorting buffer. 
Samples were resuspended in 2 ml sorting buffer and eluted with LS columns according to 
manufacturer instructions (Miltenyi Biotec).  
 
Cytofluorimetric staining and fluorescence-activated cell sorting 
After hypotonic lysis of red blood cells (when necessary), 5x105-1x106 cells were washed 
in PBS and incubated with an anti-Fc-γ receptor (2.4G2 clone) for 10 minutes at 4 °C to 
reduce unspecific binding. Samples were then stained with antibodies of interest or their 
relative isotype controls for 20 minutes at 4°C, then washed in PBS and resuspended in 
300 μl of PBS for cytofluorimetric analysis. Anti-CD11b-PerCPCy5.5, anti-GR1-APC, anti-
GR1-Pacific Blue, anti-CD115-PE, anti-CD115-APC, anti-F4/80-APCe780, anti-CD86-biotin, 
anti CD45.1-PE, anti-c-Kit-APCe780, and anti-FLT3-PE were from eBioscience; anti-IA/IE 
(MHC-II) and anti-LY6G-FITC were from BD Biosciences; anti-CD206-Alexa647, anti-LY6C-
FITC, anti-LY6C-APC, and anti-LY6G-Pacific Blue were from Biolegend. Anti-CCR2-APC was 
from R&D systems. To analyze cell viability, cells were stained with live/dead aqua dye for 
20 minutes at 4oC and then washed with PBS. Samples were acquired with a FACS LSR-II 
cytofluorimeter (BD Biosciences) and analyzed with FlowJo (Tree Star, Inc.) software. To 
perform fluorescence-activated cell sorting, cells were stained as described above, 
resuspended in FACS buffer (PBS 1X, EDTA 0.5 mM, FBS 3%, 150 U/ml streptomycin, 200 
U/ml penicillin) and then sorted with a FACS Aria (BD Biosciences). 
 
In vivo tracking of monocytes 
Tibiae and femurs of C57BL/6 and Dab2-/- healthy mice were removed with sterile 
techniques and bone marrow cells were flushed with medium. CD11b+ cells were 
enriched by immunomagnetic sorting and then stained with anti-LY6G-FITC and anti-
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CD115-PE as described above. Ly6G-CD115+ monocytes were sorted with a FACS Aria (BD 
Biosciences). Purified monocytes were labeled in PBS with 1 μM of Carboxyfluorescein 
Succinimidyl Ester (CFSE) for 5 minutes at 37 °C (Invitrogen Molecular Probe). The staining 
was blocked by adding 1/5 volume of FBS, cells were then washed twice with PBS 2% FBS 
and resuspended in culture medium. CFSE-labeled monocytes from C57Bl/6 and Dab2-/- 
were admixed 1:1 and 0.2x106 cells/mice cells were injected i.v. in tumor-bearing Ly5.1 
mice. 
 
Evaluation of CTL response (immune suppression assay)  
Mixed lymphocyte peptide culture (MLPC) on C57BL/6 background was prepared by 
mixing -irradiated C57BL/6 splenocytes with OT-1 splenocytes, in order to obtain 1% 
OVA-specific CFSE labeled lymphocytes in the final culture (typical ratio 20:1). After 5 
days, cultures were tested for ability to lyse specific target (MBL-2 loaded with the 
OVA257-264 peptide) in a 5-hour 
51Cr-release assay, using 2x103 target cells previously 
labeled with 100 µCi of Na2
51CrO4 for 60 minutes. The percentage of specific lysis was 
calculated from triplicate samples as follows: (experimental cpm x spontaneous 
cpm)/(maximal cpm x spontaneous cpm)/100. Lytic units (L.U.) were calculated as the 
number of cells giving 30% specific lysis of 2x103 specific target cells per 106 effector cells 
(L.U.30/106 cells). When present, the percent nonspecific lysis of unloaded MBL-2 control 
targets was subtracted from that obtained with MBL-2 target cells. The number of 
L.U.30/106 cells was then used to calculate L.U.30 per culture from the number of viable 
cells recovered in the cultures. The percentage of L.U.30 was calculated as follows: L.U.30 
of experimental group/L.U.30 of control group x 100 (Dolcetti, Peranzoni et al. 2010). 
 
Generation of bone marrow-derived macrophages 
Tibiae and femurs of C57BL/6 and Dab2-/- mice were removed with sterile techniques and 
bone marrow cells were flushed with medium. Red blood cells were lysed with hypotonic 
solution. To obtain macrophages from bone marrow cultures, 2.5x105 cells were plated in 
33 mm petri dishes (Falcon, Becton Dickinson) in 1.5 ml of RPMI medium supplemented 
with either GM-CSF (100 ng/ml) or M-CSF (100 ng/ml). Cultures were incubated for 7 days 
at 37°C with 5% CO2. Cells from both the non-adherent and adherent fraction were 
removed by rinsing the dishes with PBS 2mM EDTA. 
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Metastasis induction  
In order to induce lung metastasis, C57BL/6 mice and Dab2-/- transgenic mice were 
injected i.m. with 1x105 MCA-MN cells. After 26 days, when tumors exceeded 200 mm2, 
mice were euthanized and lungs were collected and fixed in Bouin solution (a picric acid, 
formalin and glacial acetic acid saturated solution). Number of lung metastasis was 
counted blindly.  
 
Statistical analysis  
Values are reported as mean ± standard error (SE). Student’s t-test was performed on 
parametric groups. Values were considered significantly with p≤0,05 and are indicated as 
*=p≤0,05; **=p≤0,01 and ***=p≤0,001. 
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Results 
 
Expression of DAB2 protein in CD11b+ myeloid cells 
According to our Affimetrix® transcriptional profiling, the Dab2 gene was overexpressed 
in intratumoral CD11b+ myeloid cells regardless of the examined tumor model and 
genetic background. To confirm these data, we analyzed DAB2 protein expression by 
immunoblot. Tumor single-cell suspensions were obtained after enzymatic digestion of 
tumor tissues, and CD11b+ myeloid cells were purified by immunomagnetic sorting. In 
accordance with the Affimetrix® profiling experiment, we used purified, splenic CD11b+ 
myeloid cells from healthy mice as control, matching for the tumor genetic background. 
Detection with a specific α-DAB2 antibody showed that both isoforms of DAB2 were 
expressed in intratumoral myeloid cells, but not in control splenic myeloid cells (Figure 1A 
and 1B). DAB2 was detected regardless of the tumor model, although we noticed a 
tumor-specific relative expression of the two DAB2 isoforms, p96 and p67. Upregulation 
of the DAB2 protein by myeloid cells was specific for the tumor microenvironment, 
because analysis of CD11b+ myeloid cells purified from the spleen (Figure 1A and 1B) and 
bone marrow (Figure 1C) of tumor-bearing mice showed no expression of the protein. 
Only injection of the C26GM tumor cell line induced a slight upregulation of the p96 
isoform in splenic myeloid cells, however this was not reproduced in other examined 
tumor models (Figure 1B). We concluded that induction of DAB2 expression in CD11b+ 
myeloid cells is a general feature of the tumor microenvironment, regardless of both the 
histologic origin of the tumor and the genetic background of the organism. 
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Figure 1. Expression of DAB2 protein in CD11b+ myeloid cells. 
Immunoblot analysis for the expression of DAB2 isoforms (p96 and p67) in CD11b+ cells isolated from the 
spleen and tumor of mice injected with different tumor cells both in (A) C57Bl/6 (EL4 and MCA203) and (B) 
BALB/c (C26GM and 4T1) backgrounds. Splenic CD11b+ cells from healthy mice matching genetic 
backgrounds were used as negative controls (ctrl). (C) Immunoblot analysis for DAB2 expression in CD11b+ 
cells isolated from the bone marrow and tumor of mice injected with MCA203 cells. Actin was used as 
loading control. 
 
Knockout of DAB2 affects accumulation of intratumoral monocytes and macrophages 
The tumor-specific induction of DAB2 in myeloid cells prompted us to speculate that this 
protein could have a specific function within the tumor microenvironment. To establish 
the consequences of DAB2 deficiency in intratumoral myeloid cells, we generated a 
conditional knockout mouse strain based on the flox/cre deletion system. The 
Dab2flox/flox;Tie2Cre+/- (Dab2-/-) mice express the CRE recombinase under the control of the 
Tie2 gene promoter, allowing a specific deletion of the floxed Dab2 gene in the 
hematopoietic precursors (Marigo, Bosio et al. 2010). 
As a model of tumor disease we chose the MCA203 fibrosarcoma cell line, which has been 
extensively used to study the altered myelopoiesis and immune tolerance induced by 
neoplastic cells (Marigo, Bosio et al. 2010; Ugel, Peranzoni et al. 2012). Subcutaneous 
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injection of MCA203 cells in Dab2-/- mice resulted in a modest delay of the tumor growth 
respect to wild type C57Bl/6 mice, as determined by daily measurement of the tumor 
area (Figure 2). 
 
Figure 2. Tumor growth is delayed in Dab2-/- mice. 
Tumor growth curve of MCA203 in C57Bl/6 and Dab2-/- mice. Animals were injected subcutaneously with 
1x106 MCA203 tumor cells. Tumors were measured blindly every 2 days with a digital caliper (N = 12, * = 
p<0.05; ** = p<0.01). 
 
We supposed that a modification of the tumor microenvironment occurs in Dab2-/- mice, 
thus resulting in a diminished growth of neoplastic cells. To understand better the nature 
of this modification, we decided to check the composition of the myeloid tumor infiltrate, 
using a multiparameter cytofluorimetric analysis of tumor-derived, single-cell 
suspensions. The analysis was performed two weeks after injection of MCA203 cells, 
when the tumor growth in Dab2-/- mice started to significantly diverge from the C57Bl/6 
group. The gating strategy for this analysis is reported in Appendix A. Strikingly, we found 
a significant reduction of intratumoral CD11b+Ly6G-Ly6ChighF4/80+ monocytes and 
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CD11b+Ly6G-Ly6Clow/negF4/80+CD115+ macrophages in Dab2-/- mice with respect to 
control. Conversely, the percentage of CD11b+Ly6G+ granulocytes was augmented within 
the tumor of Dab2-/- versus C57Bl/6 mice (Figure 3A). We also found a significant 
increment in a population of CD11b+Ly6G-F4/80-CD115- myeloid cells (either positive or 
negative for Ly6C, Fig. 3A), however we were not able to find additional markers for this 
subset, thus precluding its further characterization. 
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Figure 3. Knockout of DAB2 affects accumulation of intratumoral monocytes and macrophages. 
(A) Multicolor cytofluorimetric analysis of intratumoral myeloid cells two weeks after injection of MCA203 
cells in either C57Bl/6 or Dab2-/- mice. Analysis was performed gating on CD11b+ living cells. Populations 
were defined as described in Appendix A (Gran: granulocytes; Mono: monocytes; Mφ: macrophages). All 
graphs are representative of three independent experiments with 3-4 mice per group (* = p<0.05; *** = 
p<0.001). (B) Immunoblot analysis for DAB2 expression in intratumoral myeloid subsets, two weeks after 
injection of MCA203 cells in C57Bl/6 mice. Cells were purified by FACS; myeloid subsets were defined as 
described in Appendix A (CD11b+: total myeloid cells; Gran: granulocytes; Mono:  monocytes; Mφ: 
macrophages). (C) Thin cryosections of MCA203 tumors showing distribution of the DAB2+CD11b+ myeloid 
infiltrate. Samples were stained with α-DAB2 (red), α-CD11b (blue) and counterstained with DAPI (white). 
 
Analysis of the myeloid tumor infiltrate showed that DAB2 deficiency affects myeloid cells 
in a cell type-specific manner. For this reason we decided to better characterize DAB2 
expression in intratumoral myeloid cells. Wild type intratumoral myeloid subsets as 
defined in Figure 3A were sorted using Fluorescence Activated Cell Sorting (FACS), and 
protein lysates were analyzed for DAB2 expression by immunoblot. Interestingly, 
granulocytes had no expression of DAB2 isoforms, while both p96 and p67 were 
expressed in monocytes, macrophages and CD11b+Ly6G-F4/80- cells (Figure 3B). Relative 
expression of DAB2 isoforms was not constant in these subsets. To characterize DAB2 
expression in regard to cell position within the tumor mass, we performed confocal 
analysis of thin MCA203 tumor microsections. We found that DAB2 was preferentially 
expressed in CD11b+ myeloid cells localized to the border zone of the tumor (Figure 3C). 
All these data demonstrate that DAB2 is mainly expressed in cells of the myelomonocytic 
lineage localized to the border of the tumor mass, and its depletion affects accumulation 
of intratumoral monocytes and macrophages. 
 
Dab2-/- monocytes cannot efficiently generate intratumoral macrophages 
The reduction of intratumoral monocytes and macrophages in Dab2-/- mice could be the 
consequence of a defective myelomonocytic lineage development. This hypothesis is 
supported by the fact that DAB2 is phosphorylated following activation of the M-CSF 
signaling pathway, the main cytokine driving monocyte and macrophage differentiation 
(Cecchini, Dominguez et al. 1994; Xu, Yang et al. 1995). Moreover, the Dab2 promoter is 
transactivated in vitro by the transcription factor PU.1, which is a master regulator of 
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macrophage development (McKercher, Torbett et al. 1996; Rosenbauer, Kallies et al. 
2002). 
We decided to monitor myelopoiesis during tumor progression in Dab2-/- mice, by 
performing multiparameter cytofluorimetric analysis of ex vivo bone marrow cells. The 
gating strategy for this analysis is reported in Appendix B. Healthy Dab2-/- mice showed a 
significant reduction in the percentage of bone marrow CD11b+Ly6G-CD115+Ly6ChighCCR2+ 
inflammatory monocytes, CD11b+Ly6G-CD115+Ly6Clow/neg resident monocytes, and 
CD11b+Ly6C/G-F4/80high macrophages respect to C57Bl/6 mice, while the percentage of 
CD11b+Ly6G+ granulocytes was not affected (Figure 4A, left panel). However, the same 
analysis performed two weeks after injection of MCA203 cells showed a reduction only in 
the percentage of bone marrow macrophages in Dab2-/- mice (Figure 4A, right panel). To 
understand the reason for the constitutive lack of bone marrow monocytes in healthy 
Dab2-/- mice, we monitored the percentage of Macrophage/Dendritic Cell Progenitors 
(MDPs) (which generate monocytes) and Common Dendritic Cell Precursors (CDP) (which 
originate from MDPs). Results revealed no differences between Dab2-/- and C57Bl/6 mice, 
both under steady-state conditions and during tumor-induced myelopoiesis (Figure 4B).  
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Figure 4. Healthy Dab2-/- mice have reduced percentage of monocytes in lymphoid organs. 
(A) Multicolor cytofluorimetric analysis of bone marrow myeloid cells in C57Bl/6 versus Dab2-/- mice, both 
in healthy (left graph) and tumor-bearing (right graph) mice. Analysis was performed gating on CD11b+ 
living cells. Populations were defined as described in Appendix B and C (Gran: granulocytes; Ly6Chigh: 
inflammatory monocytes; Ly6Clow/neg: resident monocytes; Mφ: macrophages). (B) Analysis of MDPs (Lin-
CD115+FLT3+c-Kithigh cells) and CDPs (Lin-CD115+FLT3+c-Kitlow cells) in C57Bl/6 versus Dab2-/- mice, following 
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injection of MCA203 tumor cells. (C) Multicolor cytofluorimetric analysis of splenic myeloid cells in C57Bl/6 
versus Dab2-/- mice, both in healthy (left graph) and tumor-bearing (right graph) mice. Analysis was 
performed gating on CD11b+ living cells. All graphs are representative of three independent experiments 
with 3-4 mice per group (* = p<0.05; ** = p<0.01; *** = p<0.001). 
 
It was recently reported that during tumor progression, inflammatory monocytes are 
mobilized from the bone marrow and colonize a specialized niche in the spleen, where 
they induce peripheral tolerance to tumor antigens and form a pool of precursors able to 
replenish TAMs (Cortez-Retamozo, Etzrodt et al. 2012; Ugel, Peranzoni et al. 2012). 
Interestingly, in our analysis the percentage of bone marrow inflammatory monocytes, 
but not resident monocytes, was greatly diminished in wild type tumor-bearing mice with 
respect to healthy littermates (1.119±0.421% versus 5.172±0.525% respectively; Figure 
4A). We supposed that lack of bone marrow monocytes in Dab2-/- mice was masked 
during tumor progression by splenic extramedullary myelopoiesis, and that an altered 
accumulation of monocytes in this organ could explain the reduction of intratumoral 
macrophages in Dab2-/- mice. Cytofluorimetric analysis of the spleen revealed that 
healthy Dab2-/- mice had a reduced percentage of inflammatory monocytes and 
macrophages compared to C57Bl/6 mice, with a concomitant increase in the percentage 
of granulocytes (Figure 4C, left panel). However, these differences were lost two weeks 
post-injection of MCA203 cells (Figure 4C, right panel). All together, these data show that 
Dab2-/- mice have a defect in the accumulation of monocytes in lymphoid organs; 
however, this defect is lost under conditions of tumor-driven myelopoiesis, thus not 
reflecting phenotypic landscape of the tumor infiltrate. 
To understand better the reason for the lack of intratumoral monocytes and 
macrophages in Dab2-/- mice, we set up in vivo tracking of bone marrow monocytes in 
tumor-bearing mice. We purified monocytes from the bone marrow of healthy congenic 
CD45.1 wild type and CD45.2 Dab2-/- mice, using FACS. Purified cells were stained with 
the fluorescent dye CFSE and mixed 1:1, then injected in tumor bearing CD45.2 wild type 
mice (Figure 5A). Four days post-adoptive transfer of monocytes, we checked for the 
presence of CFSE+ cells in the blood and tumor of CD45.2 host mice, using 
cytofluorimetric analysis (Figure 5B). While the ratio of CFSE+ CD45.1+ wild type and 
CD45.2+Dab2-/- monocytes was 1:1 in the blood, thus demonstrating their equal access to 
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the bloodstream, this ratio dramatically changed in favor of CD45.1+ wild type monocytes 
within the tumor (Figure 5C, left). Moreover, the remaining CFSE+ CD45.2+ Dab2-/- 
monocytes seemed less prone to differentiate into macrophages with respect to CD45.1+ 
wild type monocytes (Figure 5C, right). Altogether, these data suggest that alteration of 
the tumor myeloid infiltrate in Dab2-/- mice is tumor-intrinsic and imputable to a 
defective ability of monocytes to differentiate to macrophages. 
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Figure 5. Dab2-/- monocytes cannot efficiently generate intra-tumoral macrophages 
(A) Schematic representation of the monocyte in vivo tracking experiment. (B) Gating strategy to monitor 
monocyte differentiation to macrophages. (C) The percentage of wild type versus Dab2-/- adoptively 
transferred, CFSE+ monocytes in the blood and tumor of host mice is reported on the left graph. The 
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differentiation of monocytes in macrophages was determined as the ratio between Gr-1- and Gr-1+ cells 
among CFSE+ transferred monocytes detected within the tumor (right graph; N=4 mice per group in two 
independent experiments). 
 
GM-CSF and M-CSF induce DAB2 expression in myeloid cells through a mechanism 
requiring the C/EBPβ transcription factor 
Having demonstrated that monocytes require DAB2 to differentiate in intratumoral 
macrophages, we exploited the signals required to upregulate the protein within the 
tumor. We speculated that the same stimuli, which initiate macrophage differentiation, 
were also responsible for expression of DAB2. GM-CSF and M-CSF are two cytokines 
which are abundantly secreted in the tumor microenvironment (Gabrilovich 2004); both 
of them are known to drive the differentiation of monocytes and macrophages (Hamilton 
2008). To test whether DAB2 could be upregulated in response to these stimuli, we 
purified CD11b+ cells from the spleen of wild type tumor-bearing mice using 
immunomagnetic sorting. Purified myeloid cells were exposed in vitro for 24 hours to 
GM-CSF and M-CSF alone or in combination (see Figure 6A for schematic representation 
of the experiment). Cells were harvested and protein lysates were analyzed for DAB2 
expression by immunoblot. Fresh splenic and intratumoral CD11b+ cells were used as 
negative and positive controls, respectively. We found that after exposure to either GM-
CSF, M-CSF or a combination of both, cells upregulated both DAB2 isoforms compared to 
untreated cultured cells (Figure 6B). Conversely, cells exposed to G-CSF, which drives the 
differentiation of granulocytes, did not upregulate DAB2 proteins (Figure 6C). 
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Figure 6. GM-CSF and M-CSF induce expression of DAB2 in myeloid cells. 
(A) CD11b+ myeloid cells were isolated by immunomagnetic sorting from the spleen of tumor-bearing mice. 
Purified cells were either frozen for subsequent analysis or cultured for 24 hours with or without  GM-CSF 
and M-CSF cytokines. Total cell extracts were analyzed for the expression of DAB2 isoforms by immunoblot 
(B). Intratumoral CD11b+ cells from the same mice were used as positive control for DAB2 expression. t0 = 
splenic CD11b+ cells; - = splenic CD11b+  cells in culture without cytokines; GM = as before, with GM-CSF; M 
= as before, with M-CSF; GM + M = as before, with both GM-CSF and M-CSF; + = intratumoral CD11b+ cells. 
(C) Immunoblot showing  DAB2 expression in splenic CD11b+ cells after in vitro stimulation with G-CSF. t0 = 
splenic CD11b+ cells; - = splenic CD11b+  cells in culture without cytokines; G = as before, with G-CSF; GM = 
as before, with GM-CSF; GM + G = as before, with both GM-CSF and G-CSF; + = intratumoral CD11b+ cells. 
Actin was used as loading control in all the experiments. 
 
We previously demonstrated that the C/EBPβ transcription factor is required for the in 
vivo homeostasis of CD11b+Gr-1int monocytic MDSCs, likely acting as downstream 
transcription factor for GM-CSF and IL-6 signaling pathways (Marigo, Bosio et al. 2010). In 
fact, conditional knockout of this protein in the hematopoietic system resulted in a strong 
reduction of both splenic and intratumoral monocytic MDSCs; simultaneously, the tumor 
microenvironment was radically changed, with loss of myeloid immune suppressive 
activity and reduced metastatic spreading of tumor cells (Marigo, Bosio et al. 2010). 
Having seen a relationship between DAB2 and GM-CSF, we speculated that C/EBPβ could 
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be required for expression of DAB2 in intratumoral myeloid cells. First of all, we verified 
the effects of c/EBPβ deficiency on splenic inflammatory monocytes, which are 
considered to be a fraction of monocytic MDSCs (Geissmann, Manz et al. 2010; Ugel, 
Peranzoni et al. 2012). As expected, conditional knockout of the Cebpb gene in the 
hematopoietic lineage resulted in a strong reduction of splenic CD11b+Gr-1intCD115+ 
inflammatory monocytes in tumor-bearing mice (Figure 7A). Intratumoral CD11b+ myeloid 
cells isolated from the same mice showed a dramatic depletion of the DAB2 protein with 
respect to wild type C57Bl/6 controls (Figure 7B). Altogether, these data were consistent 
with our finding that DAB2 is mainly expressed by cells of the myelomonocytic lineage 
within the tumor. Finally, we verified whether splenic Cebpb-/- CD11b+ myeloid cells could 
upregulate DAB2 in vitro. Stimulation of these cells with GM-CSF and M-CSF failed to 
induce DAB2 expression, thus supporting a role for C/EBPβ in regulating this pathway 
(Figure 7C). 
 
 
Figure 7. C/EBPβ is required for expression of DAB2 in myeloid cells. 
(A) Cytofluorimetric analysis showing accumulation of CD115+Gr-1int monocytes in the spleen of either 
C57Bl/6 or Cebpb-/- mice, two weeks after injection of MCA203 cells. Analysis was performed gating on 
CD11b+ cells. (B) Immunoblot showing expression of DAB2 in CD11b+ myeloid cells purified from tumors of 
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either C57Bl/6 or Cebpb-/- mice. Actin was used as loading control. (C) Splenic CD11b+ myeloid cells from 
either C57Bl/6 or Cebpb-/- tumor-bearing mice were purified and in vitro stimulated with both GM-CSF and 
M-CSF for 24 hours. Cells were harvested and protein lysates were analyzed for DAB2 expression by 
immunoblot (t 0 = splenic CD11b+ cells; - = splenic CD11b+ cells in culture without cytokines; GM+M = 
splenic CD11b+ cells in culture with both GM-CSF and M-CSF). Actin was used as loading control. 
 
In summary, we suggest that CD11b+ intratumoral myeloid cells upregulate DAB2 due to 
exposure to locally secreted cytokines such as GM-CSF and M-CSF. Moreover, abrogation 
of C/EBPβ transcriptional activity can impair this process. 
 
Knockout of Dab2 alters M1/M2 macrophage balance and immune suppressive activity 
within the tumor 
DAB2 depletion in myeloid cells resulted in a strong reduction of intratumoral monocytes 
and macrophages. Both cell types have main roles in the regulation of the tumor 
microenvironment: monocytes suppress antitumor adaptive immunity and can promote 
angiogenesis (De Palma, Venneri et al. 2005; Gabrilovich and Nagaraj 2009), while 
macrophages virtually control all processes which influence tumor growth and tissue 
remodeling (Qian and Pollard 2010). Having observed a reduction in the tumor growth in 
Dab2-/- mice with respect to wild type controls, we decided to measure the immune 
suppressive activity of Dab2-/- intratumoral myeloid cells. CD11b+ cells were purified with 
anti-CD11b microbeads from the tumor of Dab2-/- versus wild type mice and co-cultured 
with ovoalbumin-specific CD8+ T cells in a Mixed Lymphocyte-Peptide Culture (MLPC). 
After five days, cytotoxic activity of CD8+ T cells was evaluated with 51Chromium release 
assay. Surprisingly, we found that Dab2-/- CD11b+ myeloid cells had increased suppressive 
activity with compared to wild type ones (Figure 8A). To explain this, we checked the 
expression of immune suppressive enzymes ARG1 and iNOS in Dab2-/- intratumoral 
CD11b+ cells(Bronte and Zanovello 2005). Immunoblot revealed an increased expression 
of both enzymes in Dab2-/- samples with respect to wild type ones, which might explain 
their increased suppressive activity (Figure 8B). 
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Figure 8. Increased suppressive activity of Dab2-/- intratumoral CD11b+ myeloid cells. 
(A) Ovoalbumin (OVA) antigen specific T lymphocytes were stimulated with the OVA immunodominant 
peptide in presence of CD11b+ cells isolated from MCA203 tumors growing in either C57Bl/6 or Dab2-/- 
mice. After 5 days of culture, the cytotoxic activity of T cells was evaluated in a 51Cr release assay. Values 
are indicated as lytic unit 30% (L.U.30), as a measure of the lytic potential of T lymphocytes. Graph shows 
results from three independent experiments (N=3). (B) CD11b+ cells were purified from MCA203 tumors of 
either C57Bl/6 or Dab2-/- mice. Protein lysates were analyzed for expression of ARG1 and iNOS by 
immunoblot. Actin was used as loading control. 
 
Regulation of ARG1 and iNOS expression in macrophages is classically considered 
antithetical and a reflex of their M1/M2 polarization (Gordon and Taylor 2005), whose 
balance controls the immune response within the tumor microenvironment (Qian and 
Pollard 2010). Having seen a reduction of macrophages and an altered expression of 
ARG1 and iNOS in Dab2-/- myeloid cells, we wondered whether DAB2 deficiency could 
influence the M1/M2 polarization. Using quantitative PCR, we measured the relative 
expression of a panel of genes associated with either M1 or M2 macrophages (Murray 
and Wynn 2011). Analysis was performed on FACS-purified, intratumoral macrophages 
from either Dab2-/- or wild type tumor-bearing mice. Interestingly, Dab2-/- macrophages 
had an increased M2 signature respect to those isolated from wild type mice (Figure 9A). 
Notably, Nos2 gene expression was also increased, reflecting protein expression data 
obtained by immunoblot. To confirm further these results, we analyzed expression of 
several M1/M2 macrophage surface markers in tumor myeloid infiltrates, using 
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multiparameter cytofluorimetric analysis. In accordance with gene expression data,  
Dab2-/- mice had a reduced percentage of MHCIIhighCD86+ M1 macrophages in their tumor 
infiltrates respect to C57Bl/6 controls (Figure 8B);  moreover, CD206 expression in Dab2-/- 
macrophages was increased respect to wild type ones, suggesting a more M2-oriented 
phenotype (Figure 8C; (Mosser and Zhang 2008). Concluding, our data suggest that DAB2 
deficiency shift the balance of macrophage polarization towards the M2 status, thus 
increasing immune suppression within the tumor. 
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Figure 9. Knockout of Dab2 alters the M1/M2 balance of intratumoral macrophages. 
(A) Quantitative PCR evaluation of genes known to be associated with either M1 or M2 macrophage 
polarization. Data are expressed, on a base 2 logarithmic scale, as the fold change of mRNA abundance in 
CD11b+Ly6C/G-F4/80+ macrophages purified by FACS from MCA203 tumors of Dab2-/- mice, normalized to 
the expression of S18 housekeeping gene and compared to abundance in wild type C57BL/6 macrophages 
purified in the same way (N=4 mice per group in one experiment). (B) Top, cytofluorimetric analysis of 
tumor cell suspensions from either MCA203 tumor-bearing C57Bl/6 or Dab2-/- mice, showing the 
percentage of MHCIIhighCD86+ M1 macrophages. Analysis was performed gating on CD11b+Gr-1-F4/80+ 
macrophages. Bottom, the same gating strategy was used to analyze CD206 expression, reported as Mean 
Fluorescence Intensity (MFI; N=4 mice per group in one experiment). 
 
Dab2-/- mice have a metastasis resistant phenotype 
Metastatic spreading is a multistep process that begins in the primary tumor. Knowing 
that macrophages have a basic role in assisting all these steps, we wondered whether 
DAB2 depletion could limit the metastatic potential of tumor cells. To establish this, we 
used the MN/MCA1 sarcoma metastatic model, which induces macroscopic lung 
metastases four weeks after tumor injection (Sica, Saccani et al. 2000). In this model, we 
did not observe significant changes in the primary tumor growth between Dab2-/- and 
C57Bl/6 mice; however, the number of macrometastasis was dramatically reduced in 
Dab2-/- mice with respect to control group (Figure 10A). To confirm this result, we used 
another metastatic tumor model, the Lewis Lung Carcinoma (LLC) cell line (Kaplan, Riba et 
al. 2005). To allow direct observation of each single step of the metastatic process, we 
generated a LLC clone stably expressing the Green Fluorescent Protein (GFP). GFP 
expression allows accurate tracking of single fluorescent metastatic cells by a 
combination of in vivo imaging, confocal microscopy and quantitative-PCR of the gfp 
gene. The GFP+ LLC clone (LLC/F4) grew equally well and caused a similar composition of 
splenic, tumor and lung myeloid infiltrates with respect to its parental cell line in vivo. 
LLC/F4 growth in Dab2-/- mice was similar to its wild type counterparts (Figure 10B); 
however, even in this model we found a strong reduction of intratumoral macrophages, 
with a concomitant increase in the percentage of granulocytes (Figure 10C). To monitor 
the magnitude of the metastatic spreading, lungs were collected from tumor-bearing 
mice and total mRNA was extracted for subsequent cDNA synthesis. Presence of the gfp 
mRNA transcript was evaluated by PCR using specific primers. By this way, we could 
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detect GFP+ cells in the lungs starting from two weeks after subcutaneous injection of 
LLC/F4 cells. At this time point, the percentage of mice with GFP-positive lungs was 
reduced in the Dab2-/- group respect to wild type one (40% versus 80%, respectively). 
Three weeks after tumor injection we still found the same reduction, thus confirming an 
impairment of the metastatic spreading in Dab2-/- mice. In the present study we did not 
perform further experiments to explain these findings, which will be the aim of future 
research activity. However the LLC/F4 clone represents a tool to finely dissecting which 
steps of the metastatic process are regulated by DAB2+ myeloid cells, and how this 
regulation is accomplished. 
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Figure 10. Dab2-/- mice have a metastasis resistant phenotype. 
(A) 0.1x106 MN/MCA1 cells were intramuscularly injected in either Dab2-/- or C57Bl/6 mice. When the 
primary tumor reached 200 mm2, lungs were collected and superficial macrometastases were counted with 
Bouin staining. Number of metastases and tumor area were normalized to the C57Bl/6 group (N=22 mice 
per group, *** p<0.001). (B) Tumor growth curve of LLC/F4 in C57Bl/6 and Dab2-/- mice. Animals were 
injected subcutaneously with 2x106 LLC/F4 tumor cells. Tumors were measured blindly every 2 days with a 
digital caliper (N=8). (C) Multicolor cytofluorimetric analysis of intratumoral myeloid cells two weeks after 
injection of LLC/F4 cells in either C57Bl/6 or Dab2-/- mice. Analysis was performed gating on CD11b+ living 
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cells. Populations were defined as described in Appendix A (Gran: granulocytes; Mono: monocytes; Mφ: 
macrophages). Graph shows results from two independent experiments with 3-4 mice per group (N=8, * = 
p<0.05). (D) 2x106 LLC/F4 cells were injected subcutaneously in either C57Bl/6 or Dab2-/- mice. Mice were 
euthanized 2 (black) and 3 (red) weeks post-tumor injection and total RNA was extracted from lungs for 
subsequent cDNA synthesis. Presence of the gfp transcript was evaluated by PCR. Results are reported in 
tables on the right as percentage of mice with gfp+ lungs. 
 
Reduced number of monocytes during in vitro cultures of Dab2-/- bone marrow cells 
To describe the mechanism by which DAB2 influences the generation of intratumoral 
macrophages, we stimulated bone marrow cells with either GM-CSF or M-CSF, which 
represents a simplified in vitro model of macrophage differentiation (Fleetwood, 
Lawrence et al. 2007). Both cytokines induce expansion of bone marrow monocytes and 
their subsequent differentiation in macrophages, although with different extent and 
phenotypic traits (Hamilton 2008). As expected, treatment with either GM-CSF or M-CSF 
induced a progressive upregulation of the DAB2 protein, with a peak on day 6 (Figure 
11A). When we put in culture Dab2-/- bone marrow cells, we measured a reduced number 
of monocytes compared to wild type control, indicating a defect in the proliferation 
and/or survival of these cells if DAB2 is depleted (Figure 11B). Unexpectedly, Dab2-/- 
macrophages grew regularly during the culture, thus not reflecting the differentiation 
defect observed in vivo. These data cannot be easily reconciled with the literature and 
could indicate a DAB2- and monocyte-independent origin of the in vitro bone marrow-
derived macrophages. Further studies will be performed to address this issue. 
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Figure 11. Reduced number of monocytes during in vitro cultures of Dab2-/- bone marrow cells 
(A) Bone marrow cells collected from healthy C57Bl/6 mice were treated in vitro for 7 days with either GM-
CSF or M-CSF. Cells were collected every day and protein lysates were analyzed for DAB2 expression by 
immunoblot. Actin was used as loading control. (B) Number of monocytes (upper graphs) and macrophages 
(lower graphs) during in vitro GM-CSF/M-CSF-induced differentiation of bone marrow cells collected from 
either C57Bl/6 or Dab2-/- mice. Values were obtained multiplying the number of retrieved cells by the 
percentage of either monocytes or macrophages, as assessed by cytofluorimetric analysis. 
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Defects in the induction of autophagy during differentiation of Dab2-/- bone marrow-
derived macrophages 
It was recently published that autophagy is required for correct monocyte-macrophage 
differentiation (Jacquel, Obba et al. 2012; Zhang, Morgan et al. 2012). Knockout of the 
Atg7 gene, which impairs autophagy, caused a blockage of the differentiation of 
monocytes to macrophages. Moreover, inhibition of autophagy can lead to increased 
apoptosis (Moscat and Diaz-Meco 2009). Supposing that DAB2 deficiency induced cell 
death in monocytes, we wondered whether there could be a link between DAB2 and 
autophagy. To test this, we collected protein lysates from Dab2-/- and wild type bone 
marrow cells during M-CSF-induced macrophage differentiation. By immunoblot, we 
checked for p62 and LC3-II, two markers of autophagosome formation and degradation in 
the lysosome. Expression of p62 gradually incremented during M-CSF treatment; 
however, we measured a drastic reduction of the protein between day 6 and 7, 
suggestive of the autophagy process being activated. Interestingly, Dab2-/- bone marrow-
derived macrophages degraded p62 at a lesser extent with respect to wild type (Figure 
12A). Moreover, autophagosome formation seemed to be inhibited in Dab2-/- bone 
marrow-derived macrophages, because we detected reduced quantities of LC3-II respect 
to wild type controls, both in terms of LC3-II/LC3-I ratio and LC3-II expression per se  
(Figure 12B and 12C). Altogether, these data suggest that autophagy is inhibited when 
DAB2 is not available, and suggest a potential molecular mechanism explaining the in vivo 
and in vitro defects, which we observed in monocytes following DAB2 depletion. 
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Figure 12. Defects in the induction of autophagy during differentiation of Dab2-/- BM-derived 
macrophages. 
(A) Bone marrow cells isolated from healthy C57Bl/6 versus Dab2-/- mice were cultured with 100 ng/ml of 
M-CSF for 7 days. Protein lysates were collected at different time points and resolved on a SDS-page for 
detection of p62 protein by immunoblot. Actin was used as loading control. (B) The ratio between LC3-II 
and LC3-I in wild type versus Dab2-/- mice bone marrow-derived macrophages was quantified with ImageJ® 
after detection of the proteins by immunoblot. (C) Expression of LC3-II at day 7 in Dab2-/- bone marrow-
derived macrophages was normalized with respect to wild type control and expressed as Arbitrary Units 
(A.U.). Actin was used as loading control. 
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Discussion 
 
Macrophages are common members of the tumor microenvironment. They are found 
infiltrating many types of cancer, and their abundance usually correlates with poor 
patient prognosis (Bingle, Brown et al. 2002; Chen, Lin et al. 2005; Ryder, Ghossein et al. 
2008; Zhu, Zhang et al. 2008). This is probably due to their active contribution to almost 
all processes that sustain cancer progression (Qian and Pollard 2010). The present study 
highlights a new possible mechanism that regulates differentiation of TAMs and opening 
to additional therapeutic options for cancer patients. Based on our Affimetrix® data, the 
Dab2 gene show a strong expression in the myeloid infiltrate regardless of the histologic 
origin of the tumor; this was confirmed at protein level (Figure 1). This finding, in addition 
to our data showing a connection between the DAB2 protein and TAMs, suggests that 
artificial modulation of DAB2 expression and functions could have a beneficial therapeutic 
effect in many cancer diseases. 
According to our study, the main effect of Dab2 targeted deletion in the hematopoietic 
system is a strong reduction in monocyte and macrophage presence within the tumor. 
Cytofluorimetric analysis of the tumor infiltrate, together with in vivo monocyte tracking 
experiments strongly suggest that DAB2 is required for differentiation of TAMs (Figure 3A 
and 5); blockage of this process by DAB2 depletion also resulted in reduced accumulation 
of monocytes within the tumor, likely dependent on the negative impact on cell 
availability. At the moment we cannot exclude that DAB2 is required for the entry of 
monocytes into the tumor, a hypothesis which is supported by the notion that DAB2 
regulates integrin trafficking (Rosenbauer, Kallies et al. 2002; Chetrit, Ziv et al. 2009; 
Teckchandani, Toida et al. 2009). However our conclusion is sustained by the finding that 
in vitro macrophage differentiation of Dab2-/- bone marrow cells generated less 
monocytes compared to wild type cells (Figure 11). Interestingly, caspase activation and 
apoptosis are finely regulated during in vitro differentiation of monocytes to 
macrophages, and interfering with these pathways can lead to increased cell death 
(Meinhardt, Roth et al. 2000; Sordet, Rebe et al. 2002; Lin, Leu et al. 2011). 
The link between DAB2, macrophage differentiation and monocyte survival is further 
strengthened by our finding that both GM-CSF and M-CSF upregulate expression of the 
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protein in splenic CD11b+ myeloid cells and bone marrow cells (Figure 6 and 11A). Both 
cytokines control the proliferation, survival and differentiation of macrophages, and the 
balance between them influences the macrophage versus dendritic cell differentiation 
choice of monocytes (Menetrier-Caux, Montmain et al. 1998; Hamilton 2008). In this work 
we did not verify whether the deletion of Dab2 had consequences on the dendritic cell 
compartment too, an issue which will be addressed in future studies. If we assume that 
DAB2 expression is mandatory for macrophage differentiation, for what we know we can 
formulate at least three hypotheses regarding DAB2 function, which are not mutually 
exclusive. 
The first hypothesis consider the role of DAB2 as regulator of the integrin endocytic 
trafficking (Chetrit, Ziv et al. 2009; Teckchandani, Toida et al. 2009). It has been 
demonstrated that DAB2 regulates adhesion and spreading of macrophages in vitro 
(Rosenbauer, Kallies et al. 2002). DAB2 was shown to be phosphorylated and translocate 
from the cytosol to the cytoskeletal/membrane fraction following macrophage adhesion 
to the extracellular matrix. Forced overexpression of DAB2 leaded to increased adherence 
and spreading, suggesting that DAB2 is implicated in integrin signaling and cytoskeleton 
reorganization in macrophages (Rosenbauer, Kallies et al. 2002). Both phenomena are 
strictly interconnected to stemness and cell differentiation (Streuli 2009). Little is known 
about involvement of integrin signaling in macrophage differentiation; however, it was 
demonstrated that clustering of the β2 integrin Mac-1 (CD11b) can induce Csf1r 
expression through downregulation of the transcriptional repressor FOXP1, thus allowing 
monocyte maturation into macrophages (Shi, Zhang et al. 2004; Shi, Sakuma et al. 2008). 
Conversely, the M-CSF signaling pathway modulates integrin and cytoskeleton 
reorganization (Pixley and Stanley 2004). Considering our data regarding the tumor-
specific expression of DAB2 in myeloid cells and the in vivo behavior of adoptively 
transferred Dab2-/- monocytes (Figure 1 and 5), we can suppose that, once within the 
tumor, monocytes upregulate DAB2 in response to increased levels of tumor-secreted 
GM-CSF and M-CSF. This allows to re-organize integrins and respond to extracellular 
matrix and cell-to-cell contact stimuli, promoting intratumoral macrophage 
differentiation. Our confocal analysis of DAB2 distribution in tumor-infiltrated myeloid 
cells is in accordance with this model. We found that expression of the protein is mainly 
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localized in CD11b+ cells within the periphery of the tumor mass (Figure 3C), possibly 
indicating that DAB2 upregulation is an early event when cells infiltrate the tissue.  
The second hypothesis is based on the finding that the p67 isoform of DAB2 can 
translocate into the nucleus and function as a transcriptional activator in retinoic acid-
treated F9 cells (Cho, Jeon et al. 2000). This would add further complexity to the 
transcriptional changes orchestrated by GM-CSF and M-CSF signaling. Most important, 
this hypothesis would stress the necessity of determining the relative expression of p96 
and p67 within cells. Interestingly, we noticed a difference in the expression of DAB2 
isoforms between intratumoral monocytes and macrophages (Figure 3B). Cellular 
localization of p96 is dependent on a region of the protein which allows binding to the 
alpha-adaptin subunit of the clathrin-adaptor protein AP2 (Morris and Cooper 2001). This 
region is absent in p67, suggesting not-overlapping functions with p96. In our confocal 
studies we could not detect a nuclear distribution of the DAB2 protein in myeloid cells, 
neither in vivo nor in vitro. Nonetheless, changes in the relative expression of DAB2 
isoforms during myeloid development are a major point which needs to be addressed. 
The third hypothesis is based on our data regarding a possible involvement for DAB2 in 
autophagy. During differentiation of Dab2-/- bone marrow-derived macrophages we 
found an impairment of the autophagic process, as assessed by measurement of LC3-II 
intracellular levels and p62 degradation (Figure 12). These data can explain the negative 
impact of DAB2 depletion on macrophage differentiation, as autophagy is essential for 
the latter (Jacquel, Obba et al. 2012; Zhang, Morgan et al. 2012). Moreover, the reduced 
accumulation of transferred Dab2-/- monocytes within the tumor could be an effect of 
increased cell death caused by inefficient autophagy (Moscat and Diaz-Meco 2009). 
Although this hypothesis requires further experiments to be confirmed, evidences from 
the literature support it. Research activity in the field of autophagy has recently focused 
on where autophagosomes assume their membrane from. Presently it is believed that 
organelles such the endoplasmic reticulum, mitochondria and the Golgi complex are 
membrane sources for autophagosome formation (Mizushima and Komatsu 2011). 
However, a recent paper showed that also the plasma membrane contributes to the 
biogenesis of pre-autophagosomal structures, the so-called “phagophores” (Ravikumar, 
Moreau et al. 2010). The Authors demonstrated that ATG16L1-positive early 
autophagosome structures are generated from the plasma membrane through clathrin-
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mediated endocytosis; this requires the interaction between clathrin and ATG16L1 
through the adaptor AP2. Interestingly, knockdown of AP2 did not completely block the 
process, suggesting that other adaptor proteins could be implicated. DAB2 could be one 
of these adaptors, having already been demonstrated to substitute AP2 in endocytosis of 
LDLR (Maurer and Cooper 2006; Mulkearns and Cooper 2012). Another possibility is that 
DAB2 participates to the autophagic process through interaction of its PTB domain with 
phosphatidylinositol 4,5-bisphosphate, which promotes autophagosome biogenesis by 
influencing endocytic uptake of plasma membrane into autophagosome precursors 
(Howell, Lanier et al. 1999; Moreau, Ravikumar et al. 2012). These considerations make 
the relationship between DAB2 and autophagy quite conceivable and will be further 
explored in future studies. 
A major issue of our study is the exact origin of DAB2+ intratumoral myeloid cells, 
especially if we consider that an HSC-independent lineage of macrophages exists in 
tissues (Jenkins, Ruckerl et al. 2011; Schulz, Gomez Perdiguero et al. 2012). According to 
our immunoblot analysis, both monocytes and macrophages express DAB2 within the 
tumor (Figure 3B). At least a fraction of these DAB2+ cells probably originate from the 
blood stream, because adoptively transferred bone marrow monocytes efficiently 
generated macrophages within the tumor and splenic myeloid cells upregulated DAB2 
when properly stimulated with cytokines which induce macrophage differentiation 
(Figure 5 and 6). At the moment we cannot establish whether one or both monocyte 
subsets are the source of DAB2+ macrophages, and we do not know the anatomical site 
where they are stored (spleen or bone marrow). However, conditional knockout of the 
transcription factor c/EBPβ, which affected accumulation of splenic inflammatory 
monocytes, strongly impaired the expression of DAB2 in intratumoral CD11b+ cells, while 
splenic Cebpb-/- CD11b+ cells failed to upregulate DAB2 after in vitro stimulation with GM-
CSF and M-CSF (Figure 7). This indirectly supports the notion that inflammatory 
monocytes could, at least in part, be the source of intratumoral DAB2+ macrophages.  
Nevertheless, a population of intratumoral CD11b+Ly6G-F4/80- cells, which we were 
unable to classify, also expressed high levels of DAB2 (Figure 3). The presence of these 
cells in the myeloid tumor infiltrate increased in Dab2-/- mice with respect to wild type 
littermates, at least in the MCA203 tumor model. We can make several hypotheses 
regarding the nature of this population. If we assume that CD11b+Ly6G-F4/80- cells are 
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developmentally connected to CD11b+Ly6G/C-F4/80+ mature macrophages, they could 
represent an immature/intermediate precursor of the monocyte differentiation into 
macrophages. In this case, their accumulation within the tumor of Dab2-/- mice could be 
the consequence of the defective differentiation process. Otherwise, they could 
represent a distinct myeloid lineage, either originating from the bone marrow or 
reflecting HSC-independent local proliferation of macrophages (Jenkins, Ruckerl et al. 
2011; Schulz, Gomez Perdiguero et al. 2012). If part of the DAB2+ tumor myeloid infiltrate 
does not originate from the bone marrow, we cannot be sure that all intratumoral 
myeloid cells are targeted by conditional Dab2 deletion in Dab2flox/flox;Tie2Cre+/- mice, 
thus urging the need for alternative conditional knockout strategies. Finally, we cannot 
exclude the possibility that an impairment of the DAB2-regulated endocytic trafficking 
could alter the expression of surface markers like F4/80 and CD115, thus “masking” the 
true identity of cells when performing cytofluorimetric analysis. If this is the case, 
morphologic and confocal studies will surely be helpful in characterizing intratumoral 
CD11b+Ly6G-F4/80- cells. Noteworthy, a population of immature myeloid cells with similar 
phenotypic traits (CD11b+CD34+F4/80-Gr-1-) was shown to promote invasion of colorectal 
cancer cells by secreting MMP2 and MMP9 at the invasive front (Kitamura, Kometani et 
al. 2007). 
The concept of a partial monocyte-independent origin of macrophages comes in help 
when discussing the behavior of Dab2-/- bone marrow cells in vitro stimulated with GM-
CSF/M-CSF. Although the number of generated monocytes was diminished during the 
culture, thus reflecting our in vivo data, macrophage numbers were not affected and 
grew normally, indicating that proliferation of these cells could occur independently of 
monocyte fate (Figure 11B). Alternatively, considering that DAB2 availability is limiting for 
monocyte survival, a competition between monocyte clones could be established in 
Dab2-/- bone marrow cultures, in which those clones that stochastically do not delete the 
Dab2 gene shall prevail and replenish macrophage numbers. This possibility must be 
considered in light of the deleting efficiency of Tie2 promoter, which is not able to drive 
100% deletion in all examined mice during laboratory practice (P. Murray, personal 
communication). Finally, another technical issue concerns the inefficiency of in vitro 
differentiation systems at reproducing the complex signaling network of in vivo 
microenvironments. From this point of view, lacking of particular differentiation signals in 
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vitro could results in the discrepancies we observed during culture of Dab2-/- bone 
marrow cells. Based on the concept we discussed above regarding the role of integrins in 
regulating macrophage differentiation, we are planning to test if the use of components 
of the extracellular matrix can improve our in vitro differentiation systems. 
Although DAB2 deficiency mainly affected the differentiation of myeloid cells within the 
tumor, also the spleen and bone marrow of tumor-free mice showed reduced 
percentages of monocytes and macrophages (Figure 4). Unexpectedly, monocyte levels 
returned normal after tumor implantation, suggesting some rescue mechanisms activated 
by tumor-driven myelopoiesis. We were not able to detect DAB2 protein in CD11b+ 
myeloid cells isolated from the spleen and bone marrow, so we supposed that in these 
organs DAB2 could be expressed in Lineage- precursors of the myelomonocytic lineage, 
thus influencing the generation of monocytes. However, when we monitored the 
percentage of MDPs and CDPs during tumor progression, we did not find differences 
between Dab2-/- and wild type mice, thus excluding a defect in the generation/expansion 
of direct monocyte precursors. Noteworthy, macrophage percentages in lymphoid organs 
of Dab2-/- tumor-bearing mice were reduced despite normal monocyte levels, supporting 
the notion that DAB2 acts during macrophage maturation. 
The immunosuppressive activity of Dab2-/- intratumoral CD11b+ cells was increased 
(Figure 8A). When we measured the expression of ARG1 and iNOS enzymes, which can 
strongly suppress CD8+ T cell response, we found increased levels of both proteins in 
Dab2-/- CD11b+ tumor-infiltrating cells (Figure 8B). Considering how these enzymes are 
regulated in TAMs, we supposed that DAB2 could influence the macrophage M1/M2 
polarization (Gordon and Taylor 2005). By analyzing the expression of several genes and 
surface markers associated with either M1 or M2 status, we found that DAB2 depletion 
enhanced the M2 polarization of TAMs (Figure 9). This effect could be explained 
considering that the Dab2 gene is transcriptionally repressed by the IFN--responsive 
transcription factor IRF8 (Rosenbauer, Kallies et al. 2002). Although we do not know the 
meaning of this regulation, it is possible that DAB2 influences the macrophage response 
to IFN- and consequently, also their M1/M2 status. It should be noted that our data 
regarding macrophage polarization were obtained using the MCA203 tumor model, which 
paradoxically grew slower in Dab2-/- mice with respect to C57Bl/6 littermates (Figure 2). 
However, injection of either MN/MCA1 or LLC/F4 tumor cells did not resulted in slower 
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tumor growth (Figure 10A and 10B), suggesting that other factors, specific of the MCA203 
tumor model, concurred to alter the growth rate of tumor cells in Dab2-/- mice. 
Altogether these data suggest that DAB2 can potentially influence the immunologic 
equilibrium within the tumor. The nature of this influence could be addressed in an 
immunotherapy setting, for example by adoptively transferring tumor-specific cytotoxic 
CD8+ T cells in Dab2-/- mice to monitor their survival with respect to wild type mice. 
Abrogation of DAB2 functions in myeloid cells had the important consequence of 
hampering the metastatic potential of tumor cells, as assessed by studying two different 
metastatic tumor models (Figure 10). Considering the negative impact of DAB2 deficiency 
on macrophage differentiation, this is quite expected. However, we cannot exclude that 
DAB2 functionally participates to prometastatic functions of macrophages. From the 
invasion to the extravasation process into metastatic sites, macrophages have always 
proved to sustain complex interplays with metastatic cells (Joyce and Pollard 2009). These 
interplays require macrophages to respond to dynamically oriented stimuli in a spatial 
manner, thus conferring a fundamental role to the ability of the cells to orient its surface 
receptors and intracellular protein complexes where needed. The M-CSF/EGF paracrine 
loop described by Pollard and colleagues is an optimal example of this concept (Condeelis 
and Segall 2003; Wyckoff, Wang et al. 2004; Goswami, Sahai et al. 2005; Wyckoff, Wang 
et al. 2007). DAB2 could participate to this process in several ways, for example by 
concentrating CSF1R molecules toward extracellular M-CSF released by neighbouring 
tumor cells, or by docking integrins that interact with collagen fibers, thus allowing 
travelling through the stroma. Preliminary data obtained by our group support this 
hypothesis, as we found that DAB2 co-localizes with CSF1R+ intracellular vesicles in bone 
marrow-derived macrophages and intratumoral CD11b+ myeloid cells. Of interest, the 
DAB2 protein was found to be presented in the proteome of MDSCs isolated from 
metastatic mammary tumors (Boutte, McDonald et al. 2011). 
In conclusion, the present study reveales DAB2 to be an appealing target to hamper the 
recruitment and functionality of intratumoral myeloid cells which are of support to tumor 
progression. Block of DAB2 functions in myeloid cells, by gene silencing or 
pharmacological inhibitors, should impair accumulation and function of TAMs in cancer 
patients, with potential benefits for disease outcome. We are currently developing 
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molecular strategies to efficiently deliver small interfering RNA molecules in intratumoral 
myeloid cells, in order to silence the Dab2. 
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Appendix B: Gating strategy for myeloid cells in the spleen 
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Abbreviations 
 
AMBRA1 ............................................................................ Autophagy/beclin 1 regulator 1 
ANG ................................................................................................................. Angiopoietin 
APC ................................................................................................. Antigen presenting cell 
ARG1 .................................................................................................................. Arginase 1 
ATG ........................................................................................................ Autophagy-related 
Atg1/ULK ...................................................................................... Atg1/Unc-51-like Kinase 
AP2 ......................................................................................................... Adaptor protein 2 
Bax ............................................................................................. BCL2-associated X protein 
Bcl2 ........................................................................................................ B-cell lymphoma 2 
C/EBPβ .......................................................................... CAAT-enhancer-binding protein-β 
CCL .................................................................................................... CC-chemokine ligand 
CCR ................................................................................................ CC-chemokine receptor 
CDP ................................................................................................. Common DC precursor 
CMP ...................................................................................... Common myeloid progenitor 
COX2 ......................................................................................................... Cyclooxigenase 2 
CSC ............................................................................................................ Cancer stem cell 
CSF-1R ......................................................................................................... CSF-1 receptor 
CTL ................................................................................................. Cytotoxic T lymphocyte 
CXCL ................................................................................................ CXC-chemokine ligand 
CXCR ............................................................................................ CXC-chemokine receptor 
CX3CR1 ..................................................................................... CX3C chemokine receptor 1 
DAB2 ...................................... Disabled homolog 2, mitogen-responsive phosphoprotein 
DAMP .................................................................... Damage-associated molecular pattern 
DC ................................................................................................................... Dendritic cell 
DFCP1 ........................................................................................ FYVE-containing protein 1 
ECM ...................................................................................................... Extracellular matrix 
EGF ............................................................................................... Epidermal growth factor 
EGR1 ............................................................................................. Early growth response 1 
EMT .............................................................................. Epithelial-mesenchymal transition 
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ER ................................................................................................... Endoplasmic reticulum 
FGF ............................................................................................... Fibroblast growth factor 
FIP200 .................................. Focal adhesion kinase family interacting protein of 200 kDa 
G-CSF ...................................................................... Granulocyte colony-stimulating factor 
GM-CSF ............................................. Granulocyte/macrophage colony-stimulating factor 
GMP ......................................................................... Granulocyte-Macrophage progenitor 
HGF ............................................................................................ Hepatocyte growth factor 
HIF1α ...................................................................................... Hypoxia-inducible factor 1α 
HSC ............................................................................................... Hematopoietic stem cell 
IBD ......................................................................................... Inflammatory bowel disease 
ICAM .............................................................................. Intercellular adhesion molecule 1 
IDO........................................................................................Indoleamine 2,3-dioxygenase 
IFN ................................................................................................................... Interferon  
IL ........................................................................................................................ Interleukin 
iNOS .................................................................................... Inducible nitric oxide synthase 
IRF8 ...................................................................................... Interferon regulatory factor 8 
JNK1 ............................................................................................ c-Jun N-terminal kinase 1 
KFL4 .................................................................................................... Kruppel-like factor 4 
LC3-PE ............ Microtubule-associated protein 1 light chain 3-phospatidyl ethanolamine 
LDLR ................................................................................ Low-density lipoprotein receptor 
LOX ................................................................................................................. Lysyl oxidase 
LPS ........................................................................................................ Lipopolysaccharide 
M-CSF .................................................................... Macrophage colony-stimulating factor 
M-MDSC ........................................................ Monocytic myeloid-derived suppressor cell 
MAF ..................................................................................... Macrophage activating factor 
MAM .......................................................................... Metastasis-associated macrophage 
mDIP ......................................................................................... mDab2-interacting protein 
MDP ........................................................................................ Macrophage/DC progenitor 
MHC .............................................................................. Major histocompatibility complex 
MMP ........................................................................................... Matrix metalloproteinase 
mTORC1 ............................................................................ Target of rapamycin complex 1 
MYB ............................................................................................ Myeloblastosis oncogene 
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NFκB ........................................................................................................ Nuclear factor κB 
NK ................................................................................................................... Natural killer 
PAMP ................................................................... Pathogen-associated molecular pattern 
PAS ...................................................................................... Preautophagosomal structure 
PD1 .................................................................................Programmed cell death protein 1 
PDGF ................................................................................... Platelet-derived growth factor 
PDL1 ................................................................................................................ PD1 ligand 1 
PGE2 ......................................................................................................... Prostaglandin E2 
PI3K ........................................................... Class III phosphatidylinositol (PtdIns) 3-kinase 
PMN-MDSC ..................................... Polymorphonuclear myeloid-derived suppressor cell 
Pre-DC ........................................................................................................ Precursor of DC 
PROK2 ........................................................................................................... Prokineticin 2 
PTB ................................................................................ Phosphotyrosine-binding domain 
PtdIns ................................................................................................. Phosphatidylinositol 
RELB ............................................ Viral reticuloendotheliosis (v-rel) oncogene homolog B 
ROS ............................................................................................... Reactive oxygen species 
SCF .............................................................................................................. Stem cell factor 
SMA ................................................................................................ α-smooth muscle actin 
SQSTM1/p62 ............................................................................................. Sequestosome 1 
SRC ..................................................................... Steroid hormone receptor coactivator-1 
STAT ........................................................ Signal transducer and activator of transcription 
TAM ................................................................................. Tumor-associated macrophages 
TCR ............................................................................................................... T-cell receptor 
TEM .................................................................. Tie2-expressing monocytes/macrophages 
TGFβ .................................................................................... Transforming growth factor β 
TIDC .................................................................................. Tumor-infiltrating dendritic cell 
TipDC ................................................................... TNFα and iNOS-producing dendritic cell 
TLR ............................................................................................................ Toll-like receptor 
TNFα .............................................................................................. Tumor necrosis factor α 
TSF ........................................................................................ Tumor-derived soluble factor 
VCAM1 .......................................................................... Vascular cell adhesion molecule 1 
VEGF ............................................................................ Vascular endothelial growth factor 
96 
 
VEGFR1 ...................................................................................................... VEGF receptor 1 
Vps15 ............................................................................................ Vacuolar protein sorting 
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